{"gene":"BTG1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1992,"finding":"BTG1 was identified as an antiproliferative gene whose overexpression negatively regulates cell proliferation in NIH3T3 cells, and its expression is maximal in the G0/G1 phases of the cell cycle, decreasing as cells progress through G1.","method":"Transfection of NIH3T3 cells with BTG1 expression vector; Northern blot cell-cycle analysis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — clean overexpression with defined proliferation phenotype, single lab","pmids":["1373383"],"is_preprint":false},{"year":1996,"finding":"BTG1 (and its paralog TIS21) physically interacts with PRMT1 (protein-arginine N-methyltransferase 1) via yeast two-hybrid, and GST-BTG1 fusion protein qualitatively and quantitatively modulates endogenous PRMT1 arginine methyltransferase activity in cell extracts, identifying PRMT1 as a functional effector of BTG1.","method":"Yeast two-hybrid screen; GST pulldown; in vitro methyltransferase activity assay with cell extracts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — yeast two-hybrid plus GST pulldown plus biochemical enzyme activity assay, foundational paper with 416 citations","pmids":["8663146"],"is_preprint":false},{"year":1998,"finding":"BTG1 and BTG2 physically interact with mCaf1 (mouse CCR4-associated factor 1, a component of the yeast CCR4 transcriptional regulatory complex) both in vitro and in vivo in HeLa cells; the conserved Box B domain of BTG1 is essential for this interaction, suggesting BTG proteins participate in transcriptional regulation of cell-cycle genes via the CCR4-NOT complex.","method":"Yeast two-hybrid screening; GST pulldown (protein-binding assay); co-immunoprecipitation in HeLa cells; deletion mutagenesis of Box B","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, yeast two-hybrid, in vitro pulldown, and mutagenesis in single study with 125 citations","pmids":["9712883"],"is_preprint":false},{"year":1998,"finding":"BTG1 interaction with hCAF1 (human CCR4-associated factor 1) requires phosphorylation of Ser-159 on BTG1 by CDK2/cyclin E or CDK2/cyclin A (but not CDK4/cyclin D1 or CDC2/cyclin B); an Ala-159 mutant fails to interact with hCAF1 in yeast. In contact-inhibited smooth muscle cells, BTG1 and rCAF1 co-localize in the nucleus and co-immunoprecipitate.","method":"Yeast two-hybrid with phosphorylation-site mutants; in vitro kinase assay with purified CDKs; co-immunoprecipitation from cell extracts; immunohistochemistry; cell synchrony experiments","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro kinase assay identifying specific CDKs, mutagenesis, and co-IP validation","pmids":["9820826"],"is_preprint":false},{"year":2000,"finding":"BTG1 and BTG2 physically interact with the homeodomain transcription factor Hoxb9 via yeast two-hybrid and in vitro binding, and enhance Hoxb9-mediated transcription in transfected cells; the Hoxb9·BTG2 complex forms on a Hoxb9-responsive DNA target, facilitating Hoxb9 DNA binding. The transcriptional activation is dependent on the N-terminal activation domain of Hoxb9.","method":"Yeast two-hybrid; GST pulldown; transient transfection transcription assays; electrophoretic mobility shift assay (EMSA)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Y2H, pulldown, transcription assay, EMSA) in single study, 122 citations","pmids":["10617598"],"is_preprint":false},{"year":2001,"finding":"BTG1 and BTG2 interact with both hCAF1 and hPOP2 (human paralogs of the CCR4-associated factor). Two LXXLL nuclear receptor box motifs in BTG1 and BTG2 are required for regulation of estrogen receptor alpha (ERα)-mediated transcription; BTG proteins can act as both positive and negative regulators of ERα function, likely through a CCR4-like complex.","method":"Yeast two-hybrid; GST pulldown; co-immunoprecipitation; transient transfection luciferase transcription assays; deletion/mutagenesis of LXXLL motifs","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including mutagenesis and transcription assays, 108 citations","pmids":["11136725"],"is_preprint":false},{"year":2001,"finding":"The subcellular localization of BTG1 is controlled by multiple domains: the conserved B box mediates nuclear localization, a functional Nuclear Export Signal (NES) overlaps the B box, the first 43 N-terminal amino acids reduce nuclear accumulation, an LxxLL motif favors nuclear accumulation, and the A box inhibits nuclear localization. A nuclear-localized BTG1 mutant enhances myoblast withdrawal from the cell cycle and terminal differentiation, whereas a cytoplasmic-only mutant does not, establishing that BTG1 myogenic activity operates from the nucleus.","method":"Beta-galactosidase fusion localization assays; domain deletion/mutation constructs; transient expression in myoblasts with cell cycle and differentiation readouts","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence via domain mutagenesis","pmids":["11420681"],"is_preprint":false},{"year":2004,"finding":"FoxO3a directly targets the BTG1 promoter and induces BTG1 expression during erythroid differentiation. BTG1 expression in primary mouse bone marrow cells blocks erythroid colony outgrowth, and this anti-proliferative effect requires the domain of BTG1 that binds PRMT1. Inhibition of methyltransferase activity blocks erythroid maturation, placing the BTG1/PRMT1 axis as a downstream effector of FoxO3a in controlling erythroid expansion.","method":"Promoter-reporter assays; retroviral overexpression in primary bone marrow cells; colony formation assay; pharmacological inhibition of methyltransferase; BTG1 domain deletion mutants","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including primary cell assays, domain mutants, and pharmacological inhibition, 142 citations","pmids":["14734530"],"is_preprint":false},{"year":2004,"finding":"BTG1 overexpression in cultured endothelial cells augments tube formation and cell migration on Matrigel, while antisense BTG1 inhibits network formation; BTG1 mRNA is up-regulated in tube-forming endothelial cells and by TGF-β, defining a pro-angiogenic role for BTG1 in this cellular context.","method":"Antisense and sense BTG1 overexpression in endothelial cells; Matrigel tube formation assay; cell migration assay; neutralizing antibody against TGF-β","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — gain- and loss-of-function with specific angiogenic phenotypic readout, single lab","pmids":["15033446"],"is_preprint":false},{"year":2005,"finding":"BTG1 directly interacts with thyroid hormone receptor (T3R) and all-trans retinoic acid receptor (RAR) (but not RXRα or PPARγ), and with the myogenic factor avian MyoD (CMD1), as shown by co-immunoprecipitation in cells and GST pulldown with in vitro-synthesized proteins. These interactions are mediated by the transactivation domain of each transcription factor and the A box plus C-terminal region of BTG1. Deletion of BTG1 interacting domains abolishes its ability to stimulate nuclear receptor and CMD1 activity and its myogenic influence, establishing BTG1 as a transcriptional coactivator during myoblast differentiation.","method":"Co-immunoprecipitation in cultured myoblasts; GST pulldown with in vitro-translated proteins; transcriptional reporter assays; BTG1 deletion mutagenesis; myoblast differentiation assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro pulldown with in vitro-synthesized proteins plus cellular Co-IP plus functional mutagenesis, 57 citations","pmids":["15674337"],"is_preprint":false},{"year":2007,"finding":"BTG1 and BTG2 bind PRMT1 via their Box C region; this interaction is required for anti-IgM-induced G1 growth arrest in WEHI-231 B lymphoma cells. Pharmacological inhibition of arginine methyltransferase (AdOx) or siRNA knockdown of PRMT1 abrogates BTG1/BTG2-induced growth inhibition. Anti-IgM stimulation induces PRMT1-dependent arginine methylation of a 36-kDa protein substrate within 1-2 hours.","method":"Retroviral overexpression; flow cytometry (cell cycle); pharmacological inhibition with AdOx; siRNA knockdown of PRMT1; immunoprecipitation with anti-asymmetric dimethylarginine antibody; BTG1 domain mutagenesis (Box C)","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 — domain mutagenesis, siRNA knockdown, pharmacological inhibition all converge on PRMT1 as effector of BTG1 growth arrest, 31 citations","pmids":["17466295"],"is_preprint":false},{"year":2010,"finding":"BTG1 is a key determinant of glucocorticoid (GC) responsiveness in acute lymphoblastic leukemia: BTG1 knockdown causes GC resistance by reducing glucocorticoid receptor (GR) expression and impairing GR-mediated transcription, while BTG1 re-expression restores GC sensitivity by potentiating GC-induced GR autoinduction. PRMT1, a BTG1-binding partner, is recruited to the GR gene promoter in a BTG1-dependent manner, implicating the BTG1/PRMT1 complex as a transcriptional coactivator of GR.","method":"RNA interference (shRNA); GR expression rescue experiments; chromatin immunoprecipitation (ChIP) of PRMT1 at GR promoter; luciferase reporter assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — RNAi with defined molecular mechanism (GR autoinduction), ChIP demonstrating PRMT1 recruitment at GR promoter in BTG1-dependent manner, 66 citations","pmids":["20354172"],"is_preprint":false},{"year":2012,"finding":"Btg1 knockout mice show transient early hyperproliferation followed by progressive depletion of adult stem and progenitor cells in the dentate gyrus and subventricular zone. Adult Btg1-null stem/progenitor cells exit the cell cycle after S phase, upregulate p53 and p21, and undergo apoptosis within 5 days, indicating that Btg1 is required for maintaining adult neural stem cell quiescence and self-renewal.","method":"Btg1 knockout mouse generation; BrdU/EdU incorporation; immunofluorescence for p53, p21, activated caspase-3; neurosphere self-renewal assay; contextual memory behavioral tests","journal":"Frontiers in neuroscience","confidence":"High","confidence_rationale":"Tier 2 — clean KO with specific molecular (p53/p21 upregulation) and cellular (apoptosis, cell cycle exit) phenotype, 59 citations","pmids":["22969701"],"is_preprint":false},{"year":2015,"finding":"Btg1 regulates cerebellar granule precursor (GCP) proliferation selectively through cyclin D1: Btg1 knockout causes increased GCP proliferation and EGL hyperplasia, while gain- and loss-of-function experiments in a GCP cell line confirm that Btg1 controls proliferation via cyclin D1. Combined Btg1/Tis21 double knockout reveals additive defects in proliferation and migration. Btg1-null mice display permanent increase in adult cerebellar volume and impaired motor coordination.","method":"Btg1 single and double (Btg1/Tis21) knockout mice; BrdU incorporation; immunohistochemistry; gain- and loss-of-function in GCP cell line with cyclin D1 readout; behavioral motor testing","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — KO mice plus cell-line gain/loss-of-function with specific molecular mechanism (cyclin D1), replicated in vivo and in vitro","pmids":["26524254"],"is_preprint":false},{"year":2015,"finding":"BTG1 interacts with PRMT1 in renal cell carcinoma cells; BTG1 overexpression induces G0/G1 arrest and apoptosis in 786-O cells, and pharmacological blocking of PRMT1 activity inhibits BTG1 function, demonstrating that BTG1's anti-proliferative and pro-apoptotic effects in RCC require PRMT1 activity.","method":"Co-immunoprecipitation; BTG1 overexpression with flow cytometry (cell cycle, apoptosis); PRMT1 inhibitor treatment","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 3 — Co-IP and pharmacological inhibition with defined phenotype, single lab","pmids":["26622543"],"is_preprint":false},{"year":2016,"finding":"BTG1 interacts with ATF4 and recruits PRMT1 to methylate ATF4 at arginine residue 239, positively modulating ATF4 transcriptional activity. Loss of Btg1 in MEFs provides a survival advantage under stress conditions (hypoxia, nutrient limitation) by altering ATF4-mediated stress responses. Loss of Btg1 also enhances stress adaptation of bone marrow-derived B-cell progenitors.","method":"Btg1 knockout MEFs and B-cell progenitors; co-immunoprecipitation of BTG1-ATF4; in vitro methylation assay identifying Arg-239 as PRMT1 target; cell survival assays under stress; luciferase reporter assays for ATF4 activity","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 — co-IP plus in vitro methylation with site identification plus KO cells with defined stress-survival phenotype, 34 citations","pmids":["26657730"],"is_preprint":false},{"year":2016,"finding":"BTG1 overexpression in db/db obese mice ameliorates liver steatosis, while BTG1 knockdown induces steatosis in wild-type mice. BTG1 suppresses ATF4 activity to inhibit SCD1 (stearoyl-CoA desaturase 1) gene expression, thereby reducing hepatic triglyceride accumulation. BTG1 expression itself is regulated by the mTOR/S6K1/CREB pathway.","method":"Adenovirus-mediated overexpression/knockdown in vivo; BTG1 transgenic mice on high-carbohydrate diet; ATF4 overexpression rescue; SCD1 knockdown epistasis; hepatic lipid quantification","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain- and loss-of-function with epistasis (ATF4 rescue, SCD1 knockdown) establishing pathway position, 32 citations","pmids":["27188441"],"is_preprint":false},{"year":2015,"finding":"BTG1 regulates hepatic insulin sensitivity via upregulation of c-Jun expression: BTG1 overexpression improves insulin signaling in vitro and in vivo (db/db mice), while BTG1 knockdown impairs it. c-Jun knockdown blocks the BTG1-mediated improvement in insulin sensitivity. BTG1 promotes c-Jun expression by stimulating c-Jun and retinoic acid receptor transcriptional activities. Hepatic BTG1 is increased by leucine deprivation through the mTOR/S6K1 pathway.","method":"Adenovirus-mediated BTG1 overexpression/knockdown in vivo and in vitro; BTG1 transgenic mice; insulin tolerance and glucose tolerance tests; c-Jun knockdown epistasis; luciferase reporter assays","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain/loss-of-function with defined epistasis (c-Jun knockdown), 15 citations","pmids":["26396236"],"is_preprint":false},{"year":2020,"finding":"BTG1 and BTG2 promote mRNA deadenylation and decay to maintain T cell quiescence. BTG1/2-deficient T cells show globally increased mRNA abundance due to lengthened poly(A) tails and greater mRNA half-life, reducing the activation threshold and causing spontaneous T cell activation and proliferation. BTG1/2 thus function as regulators of the deadenylation machinery to control quiescence.","method":"BTG1/BTG2 double-knockout T cells; RNA-seq; poly(A) tail length sequencing; mRNA half-life measurement; T cell activation and proliferation assays","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — double KO with genome-wide mRNA abundance, poly(A) tail and half-life measurements plus defined cellular phenotype, 142 citations","pmids":["32165587"],"is_preprint":false},{"year":2021,"finding":"The Box C motif in BTG1 (and BTG2) is necessary and sufficient for interaction with the first RRM domain of cytoplasmic poly(A) binding protein PABPC1, and this interaction—demonstrated by NMR and mutagenesis—endows the APRO domain with the ability to stimulate mRNA deadenylation both in cellulo and in vitro. Unexpectedly, Box C is not required for BTG2 interaction with PRMT1.","method":"NMR spectroscopy; mutational analysis (Box C deletions/mutations); GST pulldown and co-immunoprecipitation; in vitro and cellular deadenylation assays","journal":"RNA biology","confidence":"High","confidence_rationale":"Tier 1 — NMR structure plus mutagenesis plus functional deadenylation assays in vitro and in cellulo","pmids":["34060423"],"is_preprint":false},{"year":2020,"finding":"Disease-associated BTG1 mutations found in non-Hodgkin lymphoma impair interaction with CNOT7 and CNOT8 (the Caf1 catalytic subunit of the CCR4-NOT deadenylase complex) and reduce BTG1 anti-proliferative activity, cell cycle inhibition, translational repression, and mRNA degradation activity, establishing loss of CCR4-NOT engagement as a mechanism of BTG1 inactivation in lymphoma.","method":"In silico selection of 16 BTG1 variants; protein-protein interaction assays with CNOT7/CNOT8; cell cycle assays; translational repression assays; mRNA degradation assays","journal":"Leukemia & lymphoma","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple functional assays with multiple mutants but single lab, 11 citations","pmids":["33021411"],"is_preprint":false},{"year":2023,"finding":"BTG1 mutations in germinal center B cells disrupt a gatekeeper mechanism limiting B cell fitness during affinity maturation, converting GC B cells into 'supercompetitors' that outstrip wild-type counterparts. This competitive advantage is conferred by a small shift in MYC protein induction kinetics and leads to aggressive invasive lymphomas. BTG1 mutations are enriched in MCD/C5 DLBCL subtype.","method":"Primary human lymphoma genomics; new mouse models of BTG1 mutation; competitive GC B cell assays; MYC induction kinetics measurement; in vivo lymphoma models","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 — mouse models plus human lymphoma data plus mechanistic link to MYC kinetics, 36 citations","pmids":["36656933"],"is_preprint":false},{"year":2023,"finding":"BTG1 inactivation accelerates lymphoproliferative disease driven by BCL2 overexpression. BTG1 directly interacts with the scaffolding protein BCAR1, and BTG1 deletion or DLBCL-associated BTG1 mutations cause overactivation of the BCAR1-RAC1 pathway, conferring increased B cell migration ability in vitro and in vivo. This is targetable with the SRC inhibitor dasatinib.","method":"Btg1 knockout mouse crossed onto Bcl2-overexpressing background; co-immunoprecipitation (BTG1-BCAR1); RAC1 activation assay; in vitro migration assays; in vivo dissemination models; dasatinib treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — Co-IP identifying novel partner BCAR1, in vivo and in vitro functional validation with pharmacological rescue, 8 citations","pmids":["36375119"],"is_preprint":false},{"year":2022,"finding":"Molecular dynamics simulations reveal that the α2-α4 interface of BTG1 undergoes conformational transitions between 'closed' and 'open' metastable states, and this interface serves as a binding hotspot for cellular partners. DLBCL mutations (Q36H, F40C, Q45P, E50K in α2; A83T, A84E in α4) either overstabilize one state or distort the helices, disrupting the dynamic equilibrium required for productive interactions with binding partners.","method":"Atomistic molecular dynamics simulations; Markov state modeling; structural analysis of WT and DLBCL mutants","journal":"Biophysical journal","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no experimental validation","pmids":["35459639"],"is_preprint":false},{"year":2023,"finding":"Btg1 and Btg2 contribute to postnatal cardiomyocyte cell cycle arrest: double knockout (DKO) mice show increased mitotic cardiomyocytes at postnatal day 7 but not day 30. AAV9-mediated double knockdown confirms increased EdU+ cardiomyocytes at P7. siRNA-mediated knockdown in neonatal rat ventricular myocytes increases EdU+ cardiomyocytes without binucleation or ploidy increase. RNAseq supports roles in inhibiting proliferation and modulating ROS response pathways.","method":"Btg1/2 double knockout mice; AAV9-shRNA knockdown; siRNA knockdown in NRVMs; EdU/pHH3 incorporation assays; RNAseq","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — double KO and knockdown with specific mitotic phenotype, multiple in vivo and in vitro approaches","pmids":["37062247"],"is_preprint":false},{"year":2015,"finding":"Targeted deletion of Btg1 and Btg2 causes homeotic transformation of the axial skeleton (posterior transformation of cervical, thoracic, and lumbar vertebrae), with Btg1 and Btg2 acting synergistically. These phenotypes are consistent with roles as modulators of Hox transcription factor function in vivo.","method":"Btg1 single KO, Btg2 single KO, and Btg1/Btg2 double KO mice; skeletal preparation and analysis of vertebral identity","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis via double KO establishing synergistic role in Hox-dependent axial patterning","pmids":["26218146"],"is_preprint":false},{"year":2015,"finding":"BTG1 expression in developing limb digit blastemas negatively influences cartilage differentiation in micromass cultures, accompanied by upregulation of Ccn1, Scleraxis, and PTHrP. BTG1 overexpression upregulates retinoic acid and thyroid hormone receptors but its connective tissue differentiation influence appears independent of these nuclear receptor signaling pathways in this context.","method":"In situ hybridization in developing limb; gain- and loss-of-function in micromass cultures; qRT-PCR for target genes","journal":"Cell and tissue research","confidence":"Low","confidence_rationale":"Tier 3 — single lab, limited mechanistic follow-up beyond target gene expression changes","pmids":["26662056"],"is_preprint":false},{"year":2021,"finding":"Chidamide (HDAC inhibitor) identifies BTG1 as a target gene in resistant B-cell lymphoma: ChIP analysis shows BTG1 is epigenetically regulated by histone deacetylase activity. BTG1 controls autophagy in rituximab/chemotherapy-resistant lymphoma cells, contributing to chidamide-induced cell death.","method":"RNA-seq; chromatin immunoprecipitation (ChIP); autophagy assays; cell death assays in resistant lymphoma cells and mouse xenograft model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP demonstrating epigenetic regulation plus functional autophagy assays, single lab","pmids":["34599153"],"is_preprint":false},{"year":2026,"finding":"BTG1 is epigenetically upregulated by HDAC inhibition in DLBCL cells and suppresses β-catenin signaling by inhibiting formation of the β-catenin/TCF4 transcriptional complex, reducing downstream targets c-Myc and Cyclin D1. BTG1 is necessary and sufficient for HDAC inhibitor-induced cell cycle arrest and autophagy in DLBCL. In vivo antitumor efficacy of HDAC inhibition depends on the BTG1/β-catenin axis.","method":"BTG1 overexpression and siRNA knockdown; co-immunoprecipitation of β-catenin/TCF4 complex; luciferase reporter for β-catenin/TCF4 activity; DLBCL xenograft mouse model; cell cycle and autophagy assays","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus in vivo epistasis but very recently published (0 citations)","pmids":["41950351"],"is_preprint":false},{"year":2020,"finding":"Loss of Btg1 in medulloblastoma (Ptch1+/- background) increases apoptosis of neoplastic cerebellar granule precursors (marked by activated caspase-3) and is associated with increased PRMT1 protein expression. Pro-apoptotic gene BAD is a PRMT1 target, suggesting increased PRMT1 activity mediates the apoptosis increase in Btg1-null tumors. Btg1 ablation also doubles CD15+ tumor stem cells in medulloblastoma.","method":"Btg1/Ptch1 double mutant mice; immunostaining for activated caspase-3 and PRMT1; CD15 staining for tumor stem cells; analysis of BAD as PRMT1 target","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vivo genetic model with mechanistic link to PRMT1/BAD pathway, but indirect evidence for PRMT1 mediating apoptosis","pmids":["32231994"],"is_preprint":false},{"year":2018,"finding":"BTG1 deficiency enhances the self-renewal of ETV6-RUNX1-positive fetal liver hematopoietic progenitors, and combined ETV6-RUNX1 expression with BTG1 loss drives upregulation of BCL6 and suppression of its targets p19Arf and Tp53. BTG1 thus limits BCL6 expression downstream of ETV6-RUNX1, acting as a tumor suppressor by restraining a BCL6-driven self-renewal program.","method":"Btg1-deficient mouse fetal liver hematopoietic progenitors; ETV6-RUNX1 retroviral expression; serial replating/self-renewal assays; gene expression analysis of BCL6, p19Arf, Tp53; ectopic BCL6 expression rescue","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in primary cells with defined pathway (BCL6 upregulation) and downstream target validation","pmids":["29408281"],"is_preprint":false},{"year":1999,"finding":"BTG1 overexpression in quail myoblasts mimics triiodothyronine (T3) and cAMP myogenic influences: it inhibits myoblast proliferation by increasing cell cycle withdrawal and stimulates terminal differentiation. T3 and cAMP stimulate BTG1 nuclear accumulation in confluent myoblasts. AP-1 activity represses BTG1 expression via an AP-1-like sequence in the BTG1 promoter, explaining low BTG1 levels in proliferating cells.","method":"Transient transfection and stable overexpression in quail myoblasts; cell cycle analysis; differentiation assays; promoter-reporter assays with AP-1 site mutation; subcellular localization by immunofluorescence","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression with proliferation/differentiation phenotype plus promoter mechanism via mutagenesis","pmids":["10366433"],"is_preprint":false},{"year":2019,"finding":"PUM2 (an RNA-binding protein) binds directly to the BTG1 3'UTR as demonstrated by RNA pulldown and RNA immunoprecipitation, repressing BTG1 expression at the post-transcriptional level. PUM2 knockdown in glioblastoma cells suppresses proliferation and migration, and these effects are reversed by BTG1 knockdown, placing BTG1 as a functional downstream target of PUM2-mediated post-transcriptional repression.","method":"RNA pulldown assay; RNA immunoprecipitation (RIP); shRNA knockdown of PUM2 and BTG1; CCK-8 proliferation assay; migration/invasion assay","journal":"Cell structure and function","confidence":"Medium","confidence_rationale":"Tier 2-3 — RNA pulldown and RIP demonstrating direct 3'UTR binding, with functional epistasis","pmids":["30787206"],"is_preprint":false}],"current_model":"BTG1 is an antiproliferative transcriptional cofactor that operates primarily through two major biochemical mechanisms: (1) interaction with PRMT1 via its Box C motif to modulate arginine methylation of substrates including ATF4 (Arg-239) and to coactivate nuclear receptors (GR, ERα, T3R, RAR) and myogenic factors, thereby regulating differentiation and stress responses; and (2) interaction with the CAF1/CCR4-NOT deadenylase complex (via Box A/B domains) and with PABPC1 (via Box C) to promote mRNA deadenylation and decay, maintaining cellular quiescence—most clearly demonstrated in T cells. BTG1 also interacts with BCAR1 to suppress RAC1-mediated B cell migration, interacts with Hoxb9 to coactivate Hox-dependent transcription, and controls neural stem cell quiescence and cardiomyocyte cell cycle arrest through cyclin D1-dependent mechanisms; disease-associated mutations in DLBCL disrupt the α2-α4 binding interface and impair CAF1/CNOT7/CNOT8 engagement, abolishing anti-proliferative activity."},"narrative":{"teleology":[{"year":1992,"claim":"The initial discovery that BTG1 overexpression inhibits NIH3T3 proliferation and that its expression peaks in G0/G1 established BTG1 as an antiproliferative gene linked to cell cycle exit.","evidence":"Transfection of NIH3T3 cells with BTG1 expression vector; Northern blot cell-cycle analysis","pmids":["1373383"],"confidence":"Medium","gaps":["Mechanism of growth inhibition unknown","No binding partners identified","No in vivo validation"]},{"year":1996,"claim":"Identification of PRMT1 as a direct BTG1-interacting partner that modulates arginine methyltransferase activity revealed the first biochemical effector mechanism for BTG1's cellular functions.","evidence":"Yeast two-hybrid screen; GST pulldown; in vitro methyltransferase activity assay","pmids":["8663146"],"confidence":"High","gaps":["Substrates of PRMT1 methylation downstream of BTG1 unknown","In vivo relevance not yet tested"]},{"year":1998,"claim":"Discovery that BTG1 binds CAF1/CCR4-NOT complex components via Box B, with the interaction regulated by CDK2-mediated Ser-159 phosphorylation, established a second major effector axis and linked BTG1 to transcriptional/post-transcriptional regulation via the CCR4 complex.","evidence":"Yeast two-hybrid; GST pulldown; Co-IP; in vitro kinase assay with purified CDKs; phosphorylation-site mutagenesis","pmids":["9712883","9820826"],"confidence":"High","gaps":["Whether CAF1 interaction mediates deadenylation not yet tested","Functional consequence of Ser-159 phosphorylation on cell proliferation unresolved"]},{"year":2000,"claim":"Demonstration that BTG1 enhances Hoxb9-mediated transcription by stabilizing Hoxb9 DNA binding expanded the gene's role to transcriptional coactivation beyond the PRMT1 axis, and predicted developmental phenotypes.","evidence":"Yeast two-hybrid; GST pulldown; transient transfection reporter assays; EMSA","pmids":["10617598"],"confidence":"High","gaps":["In vivo Hox-dependent developmental role not demonstrated","Whether BTG1 coactivation is direct or through adaptor recruitment unclear"]},{"year":2001,"claim":"Identification of LXXLL nuclear receptor box motifs as required for ERα regulation and mapping of localization signals showed that BTG1 acts as a nuclear transcriptional coactivator of nuclear receptors and that its nuclear localization is essential for myogenic differentiation activity.","evidence":"Co-IP; mutagenesis of LXXLL motifs; luciferase reporter assays; β-galactosidase fusion localization assays; myoblast differentiation readouts","pmids":["11136725","11420681"],"confidence":"High","gaps":["Whether ER regulation operates through PRMT1 or CAF1 arm unclear","Endogenous target genes of BTG1-nuclear receptor complexes not identified"]},{"year":2004,"claim":"Positioning BTG1 as a FoxO3a transcriptional target that requires its PRMT1-binding domain to block erythroid colony outgrowth placed the BTG1/PRMT1 axis within a defined upstream signaling hierarchy controlling hematopoietic progenitor proliferation.","evidence":"Promoter-reporter assays; retroviral overexpression in primary bone marrow cells; colony assays; pharmacological methyltransferase inhibition; domain deletion mutants","pmids":["14734530"],"confidence":"High","gaps":["PRMT1 substrates mediating erythroid arrest not identified","Whether FoxO3a-BTG1-PRMT1 axis operates in other lineages untested"]},{"year":2005,"claim":"Direct binding of BTG1 to T3R, RAR, and avian MyoD via A box/C-terminal domains, with mutagenesis showing these interactions are required for both transcriptional activation and myogenic differentiation, consolidated BTG1's identity as a multi-nuclear-receptor coactivator.","evidence":"Co-IP in myoblasts; GST pulldown with in vitro-translated proteins; transcriptional reporter assays; domain deletion mutagenesis","pmids":["15674337"],"confidence":"High","gaps":["Whether coactivation involves PRMT1-dependent chromatin modification at target genes unknown","Genome-wide targets in myogenesis not mapped"]},{"year":2007,"claim":"Demonstration that Box C-mediated PRMT1 binding is required for anti-IgM-induced G1 arrest in B lymphoma cells, confirmed by both siRNA and pharmacological inhibition, established PRMT1 as the essential effector of BTG1 growth arrest in B cells.","evidence":"Retroviral overexpression; flow cytometry; PRMT1 siRNA; AdOx inhibition; Box C mutagenesis; immunoprecipitation with anti-dimethylarginine antibody","pmids":["17466295"],"confidence":"High","gaps":["Identity of the 36-kDa methylated substrate unknown","Whether the CAF1-binding arm also contributes to B cell growth arrest untested"]},{"year":2010,"claim":"BTG1 was shown to determine glucocorticoid sensitivity in ALL by recruiting PRMT1 to the GR promoter in a BTG1-dependent manner, enabling GR autoinduction — the first ChIP-based evidence placing the BTG1/PRMT1 complex at a defined chromatin locus.","evidence":"shRNA knockdown; GR expression rescue; ChIP of PRMT1 at GR promoter; luciferase reporter assays","pmids":["20354172"],"confidence":"High","gaps":["Whether PRMT1-catalyzed histone methylation or non-histone substrate methylation mediates GR induction unclear","Clinical validation in ALL patients lacking"]},{"year":2012,"claim":"Btg1 knockout mice revealed that Btg1 is essential for maintaining adult neural stem cell quiescence: loss causes transient hyperproliferation followed by p53/p21-dependent apoptosis and progressive stem cell depletion, providing the first in vivo demonstration that Btg1 safeguards stem cell pools.","evidence":"Btg1 KO mice; BrdU/EdU incorporation; immunofluorescence for p53, p21, activated caspase-3; neurosphere self-renewal assay","pmids":["22969701"],"confidence":"High","gaps":["Direct molecular targets of BTG1 in neural stem cells not identified","Whether PRMT1 or CAF1 arm mediates quiescence in this niche unknown"]},{"year":2015,"claim":"Multiple in vivo studies converged to show BTG1 controls cyclin D1-dependent cerebellar granule precursor proliferation, synergizes with BTG2 in Hox-dependent axial skeleton patterning, and modulates ATF4 methylation at Arg-239 to regulate stress adaptation — establishing BTG1 as a pleiotropic developmental and stress-response regulator acting through distinct molecular effectors.","evidence":"Btg1 and Btg1/Btg2 DKO mice; skeletal preparations; cyclin D1 readouts in GCP cell line; co-IP of BTG1-ATF4; in vitro methylation identifying Arg-239; stress survival assays in KO MEFs and B-cell progenitors","pmids":["26524254","26524254","26657730","26396236"],"confidence":"High","gaps":["Whether cyclin D1 regulation is direct or indirect unclear","Structural basis for ATF4 methylation site selectivity unknown"]},{"year":2016,"claim":"BTG1 was placed within the mTOR/S6K1/CREB regulatory axis in hepatocytes, where it suppresses ATF4-driven SCD1 expression to prevent steatosis and improves insulin sensitivity via c-Jun upregulation, extending its antiproliferative cofactor role to metabolic homeostasis.","evidence":"Adenovirus-mediated overexpression/knockdown in vivo; BTG1 transgenic mice; ATF4 overexpression rescue; SCD1 knockdown epistasis; insulin and glucose tolerance tests","pmids":["27188441","26396236"],"confidence":"High","gaps":["Whether the hepatic metabolic role requires PRMT1 enzymatic activity not directly tested","Human liver disease relevance not established"]},{"year":2020,"claim":"The deadenylation function of BTG1/2 was definitively established: double-knockout T cells showed globally lengthened poly(A) tails and increased mRNA half-lives causing spontaneous activation, while lymphoma-associated BTG1 mutations were shown to disrupt CNOT7/CNOT8 binding and abolish antiproliferative and mRNA decay activity.","evidence":"BTG1/2 DKO T cells; RNA-seq; poly(A) tail sequencing; mRNA half-life measurement; functional assays of 16 DLBCL BTG1 variants for CNOT7/CNOT8 binding and antiproliferative activity","pmids":["32165587","33021411"],"confidence":"High","gaps":["Whether specific mRNA targets mediate the quiescence phenotype or the effect is global remains unclear","Relative contribution of PRMT1 versus CAF1/PABPC1 arms to BTG1 tumor suppression in lymphoma unresolved"]},{"year":2021,"claim":"NMR-based structural dissection showed the Box C motif is necessary and sufficient for PABPC1 interaction and stimulation of mRNA deadenylation, completing the molecular anatomy of the BTG1 deadenylation axis (Box A/B for CAF1, Box C for PABPC1).","evidence":"NMR spectroscopy; Box C mutational analysis; GST pulldown; co-IP; in vitro and cellular deadenylation assays","pmids":["34060423"],"confidence":"High","gaps":["Full structure of BTG1-PABPC1-CAF1 ternary complex not determined","Whether PABPC1 binding is regulated by post-translational modification unknown"]},{"year":2023,"claim":"BTG1 mutations in germinal center B cells were shown to create supercompetitors via altered MYC induction kinetics, and BTG1 loss was found to activate a BCAR1-RAC1 migration pathway targetable by dasatinib, revealing two distinct pathogenic mechanisms in DLBCL.","evidence":"Mouse models of BTG1 mutation; competitive GC B cell assays; MYC induction kinetics; Co-IP of BTG1-BCAR1; RAC1 activation and migration assays; dasatinib treatment in vivo","pmids":["36656933","36375119"],"confidence":"High","gaps":["Whether MYC kinetics shift is mediated through the deadenylation or PRMT1 arm not determined","Clinical efficacy of dasatinib in BTG1-mutant DLBCL unvalidated","BCAR1 interaction domain on BTG1 not mapped"]},{"year":null,"claim":"A unified quantitative model of how the PRMT1-dependent and CAF1/PABPC1-dependent arms of BTG1 are coordinately deployed in different cellular contexts — and which arm is dominant for tumor suppression in specific cancer types — remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of full-length BTG1 in complex with both PRMT1 and CAF1/PABPC1","Genome-wide identification of mRNA targets whose deadenylation is BTG1-dependent in normal versus malignant B cells lacking","Context-dependent relative contributions of PRMT1 and deadenylation arms to tumor suppression not dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4,5,9,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,7,10,15,18,19]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,5,9,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,6,11]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,19]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,10,13,24]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,9,11]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[18,19,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,13,25]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18,21,22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[12,14,29]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,17]}],"complexes":["CCR4-NOT deadenylase complex"],"partners":["PRMT1","CNOT7","CNOT8","PABPC1","BCAR1","ATF4","HOXB9","NR3C1"],"other_free_text":[]},"mechanistic_narrative":"BTG1 is an antiproliferative transcriptional cofactor and mRNA decay regulator that enforces cellular quiescence and controls differentiation across multiple lineages. It exerts its functions through two principal biochemical axes: interaction with PRMT1 via its Box C motif to modulate arginine methylation of substrates such as ATF4 (Arg-239) and to coactivate nuclear receptors (GR, ERα, T3R, RAR) and myogenic factors, thereby linking cell cycle arrest to transcriptional programs in erythroid, B cell, hepatic, and muscle differentiation contexts [PMID:8663146, PMID:15674337, PMID:20354172, PMID:26657730]; and interaction with the CAF1/CCR4-NOT deadenylase complex (via Box A/B domains) and PABPC1 (via Box C), promoting mRNA deadenylation and decay that maintains quiescence — most clearly demonstrated by globally increased mRNA stability and spontaneous T cell activation in BTG1/2 double-knockout T cells [PMID:32165587, PMID:34060423]. Loss-of-function BTG1 mutations recurrent in diffuse large B cell lymphoma disrupt the α2–α4 binding interface required for CAF1/CNOT7/CNOT8 engagement, abolishing antiproliferative activity and converting germinal center B cells into supercompetitors with altered MYC induction kinetics that drive aggressive lymphomagenesis [PMID:33021411, PMID:36656933]. In vivo, Btg1 deletion causes hyperproliferation followed by stem/progenitor depletion in adult neural niches, increased cardiomyocyte mitosis postnatally, and homeotic skeletal transformations consistent with Hox cofactor function [PMID:22969701, PMID:26524254, PMID:26218146]."},"prefetch_data":{"uniprot":{"accession":"P62324","full_name":"Protein BTG1","aliases":["B-cell translocation gene 1 protein"],"length_aa":171,"mass_kda":19.2,"function":"Anti-proliferative protein","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P62324/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTG1","classification":"Not Classified","n_dependent_lines":35,"n_total_lines":1208,"dependency_fraction":0.028973509933774833},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BTG1","total_profiled":1310},"omim":[{"mim_id":"612868","title":"CORNEAL DYSTROPHY, POSTERIOR AMORPHOUS; PACD","url":"https://www.omim.org/entry/612868"},{"mim_id":"607396","title":"TRANSDUCER OF ERBB2, 2; TOB2","url":"https://www.omim.org/entry/607396"},{"mim_id":"605674","title":"B-CELL ANTIPROLIFERATION FACTOR 3; BTG3","url":"https://www.omim.org/entry/605674"},{"mim_id":"605523","title":"TRANSDUCER OF ERBB2, 1; TOB1","url":"https://www.omim.org/entry/605523"},{"mim_id":"605027","title":"LYMPHOMA, NON-HODGKIN, FAMILIAL","url":"https://www.omim.org/entry/605027"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":88.7}],"url":"https://www.proteinatlas.org/search/BTG1"},"hgnc":{"alias_symbol":["APRO2"],"prev_symbol":[]},"alphafold":{"accession":"P62324","domains":[{"cath_id":"3.90.640.90","chopping":"2-128","consensus_level":"high","plddt":93.5002,"start":2,"end":128}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P62324","model_url":"https://alphafold.ebi.ac.uk/files/AF-P62324-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P62324-F1-predicted_aligned_error_v6.png","plddt_mean":81.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTG1","jax_strain_url":"https://www.jax.org/strain/search?query=BTG1"},"sequence":{"accession":"P62324","fasta_url":"https://rest.uniprot.org/uniprotkb/P62324.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P62324/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P62324"}},"corpus_meta":[{"pmid":"8663146","id":"PMC_8663146","title":"The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663146","citation_count":416,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1373383","id":"PMC_1373383","title":"BTG1, a member of a new family of antiproliferative genes.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1373383","citation_count":276,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11377414","id":"PMC_11377414","title":"In search of a function for the TIS21/PC3/BTG1/TOB family.","date":"2001","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11377414","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30350856","id":"PMC_30350856","title":"Tumor suppressors BTG1 and BTG2: Beyond growth control.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30350856","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32165587","id":"PMC_32165587","title":"mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32165587","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14734530","id":"PMC_14734530","title":"FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/14734530","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10602502","id":"PMC_10602502","title":"Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10602502","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9712883","id":"PMC_9712883","title":"Interaction of BTG1 and p53-regulated BTG2 gene products with mCaf1, the murine homolog of a component of the yeast CCR4 transcriptional regulatory complex.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9712883","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28193514","id":"PMC_28193514","title":"MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1.","date":"2017","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28193514","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10617598","id":"PMC_10617598","title":"The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10617598","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11136725","id":"PMC_11136725","title":"Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: involvement in estrogen receptor alpha signaling pathway.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11136725","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9632145","id":"PMC_9632145","title":"ANA, a novel member of Tob/BTG1 family, is expressed in the ventricular zone of the developing central nervous system.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9632145","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9820826","id":"PMC_9820826","title":"Human carbon catabolite repressor protein (CCR4)-associative factor 1: cloning, expression and characterization of its interaction with the B-cell translocation protein BTG1.","date":"1998","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9820826","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22359517","id":"PMC_22359517","title":"The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22359517","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20354172","id":"PMC_20354172","title":"BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20354172","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31452761","id":"PMC_31452761","title":"miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31452761","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22969701","id":"PMC_22969701","title":"Btg1 is Required to Maintain the Pool of Stem and Progenitor Cells of the Dentate Gyrus and Subventricular Zone.","date":"2012","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22969701","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15674337","id":"PMC_15674337","title":"Coactivation of nuclear receptors and myogenic factors induces the major BTG1 influence on muscle differentiation.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15674337","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31632519","id":"PMC_31632519","title":"Lidocaine inhibits cervical cancer cell proliferation and induces cell apoptosis by modulating the lncRNA-MEG3/miR-421/BTG1 pathway.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/31632519","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27979924","id":"PMC_27979924","title":"Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.","date":"2016","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/27979924","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10366433","id":"PMC_10366433","title":"BTG1: a triiodothyronine target involved in the myogenic influence of the hormone.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10366433","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30835506","id":"PMC_30835506","title":"MicroRNA-183 inhibition exerts suppressive effects on diabetic retinopathy by inactivating BTG1-mediated PI3K/Akt/VEGF signaling pathway.","date":"2019","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30835506","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9690562","id":"PMC_9690562","title":"Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human.","date":"1998","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9690562","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25936765","id":"PMC_25936765","title":"MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1.","date":"2015","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/25936765","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23982470","id":"PMC_23982470","title":"BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23982470","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25115181","id":"PMC_25115181","title":"Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells.","date":"2014","source":"Radiation oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25115181","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15033446","id":"PMC_15033446","title":"An anti-proliferative gene BTG1 regulates angiogenesis in vitro.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15033446","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35880434","id":"PMC_35880434","title":"Emerging role of anti-proliferative protein BTG1 and BTG2.","date":"2022","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/35880434","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36656933","id":"PMC_36656933","title":"BTG1 mutation yields supercompetitive B cells primed for malignant transformation.","date":"2023","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36656933","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26657730","id":"PMC_26657730","title":"Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26657730","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8325512","id":"PMC_8325512","title":"Sequence analysis reveals that the BTG1 anti-proliferative gene is conserved throughout evolution in its coding and 3' non-coding regions.","date":"1993","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8325512","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27188441","id":"PMC_27188441","title":"BTG1 ameliorates liver steatosis by decreasing stearoyl-CoA desaturase 1 (SCD1) abundance and altering hepatic lipid metabolism.","date":"2016","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/27188441","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17466295","id":"PMC_17466295","title":"Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17466295","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30515803","id":"PMC_30515803","title":"Long noncoding RNA DGCR5 suppresses gastric cancer progression by acting as a competing endogenous RNA of PTEN and BTG1.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30515803","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28247022","id":"PMC_28247022","title":"Physical exercise rescues defective neural stem cells and neurogenesis in the adult subventricular zone of Btg1 knockout mice.","date":"2017","source":"Brain structure & function","url":"https://pubmed.ncbi.nlm.nih.gov/28247022","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26524254","id":"PMC_26524254","title":"Altered cerebellum development and impaired motor coordination in mice lacking the Btg1 gene: Involvement of cyclin D1.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26524254","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34599153","id":"PMC_34599153","title":"Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34599153","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24084718","id":"PMC_24084718","title":"BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas.","date":"2013","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24084718","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11420681","id":"PMC_11420681","title":"Identification of functional domains involved in BTG1 cell localization.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11420681","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24264312","id":"PMC_24264312","title":"The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24264312","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27904689","id":"PMC_27904689","title":"MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27904689","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9286591","id":"PMC_9286591","title":"Sequence and developmental expression of AmphiTob, an amphioxus homolog of vertebrate Tob in the PC3/BTG1/Tob family of tumor suppressor genes.","date":"1997","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/9286591","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25967096","id":"PMC_25967096","title":"Control of the Normal and Pathological Development of Neural Stem and Progenitor Cells by the PC3/Tis21/Btg2 and Btg1 Genes.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25967096","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31486488","id":"PMC_31486488","title":"Abnormal expression and mechanism of miR-330-3p/BTG1 axis in hepatocellular carcinoma.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31486488","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27447746","id":"PMC_27447746","title":"BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27447746","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22072402","id":"PMC_22072402","title":"High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22072402","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24272202","id":"PMC_24272202","title":"BTG1 expression correlates with the pathogenesis and progression of breast carcinomas.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24272202","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26622543","id":"PMC_26622543","title":"BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26622543","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28603285","id":"PMC_28603285","title":"miR-511 promotes the proliferation of human hepatoma cells by targeting the 3'UTR of B cell translocation gene 1 (BTG1) mRNA.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28603285","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24985971","id":"PMC_24985971","title":"The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24985971","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26503430","id":"PMC_26503430","title":"Upregulation of BTG1 enhances the radiation sensitivity of human breast cancer in vitro and in vivo.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26503430","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30787206","id":"PMC_30787206","title":"PUM2 Promotes Glioblastoma Cell Proliferation and Migration via Repressing BTG1 Expression.","date":"2019","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/30787206","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33330092","id":"PMC_33330092","title":"BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial-Mesenchymal Transition.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33330092","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26396236","id":"PMC_26396236","title":"A novel function of B-cell translocation gene 1 (BTG1) in the regulation of hepatic insulin sensitivity in mice via c-Jun.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/26396236","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35561854","id":"PMC_35561854","title":"ASIC1a promotes hepatic stellate cell activation through the exosomal miR-301a-3p/BTG1 pathway.","date":"2022","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35561854","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33760119","id":"PMC_33760119","title":"Exosomal microRNA-301a-3p promotes the proliferation and invasion of nasopharyngeal carcinoma cells by targeting BTG1 mRNA.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33760119","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31410369","id":"PMC_31410369","title":"microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.","date":"2019","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/31410369","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25173640","id":"PMC_25173640","title":"Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25173640","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26218146","id":"PMC_26218146","title":"Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26218146","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34060423","id":"PMC_34060423","title":"A conserved motif in human BTG1 and BTG2 proteins mediates interaction with the poly(A) binding protein PABPC1 to stimulate mRNA deadenylation.","date":"2021","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/34060423","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33021411","id":"PMC_33021411","title":"Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma.","date":"2020","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/33021411","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32733254","id":"PMC_32733254","title":"Homoharringtonine Inhibits Allergic Inflammations by Regulating NF-κB-miR-183-5p-BTG1 Axis.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32733254","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16786164","id":"PMC_16786164","title":"Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16786164","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37062247","id":"PMC_37062247","title":"Btg1 and Btg2 regulate neonatal cardiomyocyte cell cycle arrest.","date":"2023","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/37062247","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35459639","id":"PMC_35459639","title":"Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants.","date":"2022","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/35459639","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36375119","id":"PMC_36375119","title":"BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36375119","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11310585","id":"PMC_11310585","title":"Identification and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes.","date":"2001","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11310585","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34767738","id":"PMC_34767738","title":"miR-141-5p Affects the Cell Proliferation and Apoptosis by Targeting BTG1 in Cervical Cancer.","date":"2021","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/34767738","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34934442","id":"PMC_34934442","title":"MicroRNA-208a-3p participates in coronary heart disease by regulating the growth of hVSMCs by targeting BTG1.","date":"2021","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34934442","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19515430","id":"PMC_19515430","title":"Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis.","date":"2009","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/19515430","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24998463","id":"PMC_24998463","title":"High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.","date":"2014","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24998463","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32231994","id":"PMC_32231994","title":"Deletion of Btg1 Induces Prmt1-Dependent Apoptosis and Increased Stemness in Shh-Type Medulloblastoma Cells Without Affecting Tumor Frequency.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32231994","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26665453","id":"PMC_26665453","title":"[Expression of BTG1 protein in laryngeal squamous cell carcinoma and its clinical significance].","date":"2015","source":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery","url":"https://pubmed.ncbi.nlm.nih.gov/26665453","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29408281","id":"PMC_29408281","title":"Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.","date":"2018","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29408281","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25297078","id":"PMC_25297078","title":"Molecular cloning, sequence analysis, and cadmium stress-rated expression changes of BTG1 in freshwater pearl mussel (Hyriopsis schlegelii).","date":"2014","source":"Dong wu xue yan jiu = Zoological research","url":"https://pubmed.ncbi.nlm.nih.gov/25297078","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37187949","id":"PMC_37187949","title":"Targeting a novel circITCH/miR-421/BTG1 axis is effective to suppress the malignant phenotypes in hepatocellular carcinoma (HCC) cells.","date":"2023","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37187949","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26662056","id":"PMC_26662056","title":"The tumor suppressor BTG1 is expressed in the developing digits and regulates skeletogenic differentiation of limb mesodermal progenitors in high density cultures.","date":"2015","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/26662056","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28469801","id":"PMC_28469801","title":"Erratum: MiR-4295 promotes cell growth in bladder cancer by targeting BTG1.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28469801","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32166669","id":"PMC_32166669","title":"Identification of BTG1 Status in Solid Cancer for Future Researches Using a System Review and Meta-analysis.","date":"2020","source":"Current medical science","url":"https://pubmed.ncbi.nlm.nih.gov/32166669","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39095315","id":"PMC_39095315","title":"IKZF1 and BTG1 silencing reduces glucocorticoid response in B-cell precursor acute leukemia cell line.","date":"2024","source":"Hematology, transfusion and cell therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39095315","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38254153","id":"PMC_38254153","title":"The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.","date":"2024","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/38254153","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36705483","id":"PMC_36705483","title":"Mutations in BTG1 Promote Germinal Center B-cell Malignant Transformation.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36705483","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34109351","id":"PMC_34109351","title":"[Expression and clinical significance of BTG-1 in 78 patients with oral squamous cell carcinoma].","date":"2021","source":"Shanghai kou qiang yi xue = Shanghai journal of stomatology","url":"https://pubmed.ncbi.nlm.nih.gov/34109351","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41950351","id":"PMC_41950351","title":"BTG1 Acts as a Critical Tumor Suppressor Link Between HDAC Inhibition and β-Catenin Signaling Suppression in Diffuse Large B-Cell Lymphoma.","date":"2026","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/41950351","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36746366","id":"PMC_36746366","title":"Expanding the phenotype of 12q21 deletions: A role of BTG1 in speech development?","date":"2023","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36746366","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.22.24315961","title":"Genomic Landscape and Molecular Subtypes of Primary Central Nervous System Lymphoma","date":"2024-10-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.22.24315961","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12665801","id":"PMC_12665801","title":"Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12665801","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"426909","id":"PMC_426909","title":"Platelet alpha-granule proteins: studies on release and subcellular localization.","date":"1979","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/426909","citation_count":464,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8702798","id":"PMC_8702798","title":"The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702798","citation_count":354,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10877842","id":"PMC_10877842","title":"Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10877842","citation_count":261,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900206","id":"PMC_21900206","title":"A directed protein interaction network for investigating intracellular signal transduction.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21900206","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2834384","id":"PMC_2834384","title":"Presence of three distinct molecular species of Gi protein alpha subunit. Structure of rat cDNAs and human genomic DNAs.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2834384","citation_count":256,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"47244","id":"PMC_47244","title":"The isolation and characterisation of a platelet-specific beta-globulin (beta-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets.","date":"1975","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/47244","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"77677","id":"PMC_77677","title":"Complete covalent structure of human beta-thromboglobulin.","date":"1978","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/77677","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6572368","id":"PMC_6572368","title":"Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor.","date":"1983","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6572368","citation_count":190,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2406364","id":"PMC_2406364","title":"Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases.","date":"1990","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2406364","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2007144","id":"PMC_2007144","title":"Chemical synthesis, purification, and characterization of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide.","date":"1991","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2007144","citation_count":152,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17192395","id":"PMC_17192395","title":"Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17192395","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22916037","id":"PMC_22916037","title":"Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22916037","citation_count":132,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2423119","id":"PMC_2423119","title":"Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and beta-thromboglobulin.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2423119","citation_count":121,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28381538","id":"PMC_28381538","title":"Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation.","date":"2017","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28381538","citation_count":120,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25858640","id":"PMC_25858640","title":"Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis.","date":"2015","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25858640","citation_count":108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8580362","id":"PMC_8580362","title":"Chemokine and chemokine receptor mRNA expression in human platelets.","date":"1995","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/8580362","citation_count":105,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2522778","id":"PMC_2522778","title":"A novel cleavage product of beta-thromboglobulin formed in cultures of stimulated mononuclear cells activates human neutrophils.","date":"1989","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2522778","citation_count":100,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12193731","id":"PMC_12193731","title":"Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12193731","citation_count":93,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15340161","id":"PMC_15340161","title":"Signal peptide prediction based on analysis of experimentally verified cleavage sites.","date":"2004","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/15340161","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18240029","id":"PMC_18240029","title":"Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.","date":"2008","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18240029","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43365,"output_tokens":6736,"usd":0.115568},"stage2":{"model":"claude-opus-4-6","input_tokens":10418,"output_tokens":4009,"usd":0.228472},"total_usd":0.761475,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":56810,"output_tokens":9518,"usd":0.1566},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":13218,"output_tokens":4312,"usd":0.260835}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"BTG1 protein physically interacts with PRMT1 (protein-arginine N-methyltransferase 1) and modulates its enzymatic activity; GST-BTG1 fusion proteins qualitatively and quantitatively alter endogenous PRMT1 activity, producing NG-monomethyl and asymmetric NG,NG-dimethylarginine on protein substrates.\",\n      \"method\": \"Yeast two-hybrid screening, GST pulldown, in vitro methyltransferase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of enzymatic activity with GST fusion proteins, two-hybrid identification, replicated in multiple subsequent studies\",\n      \"pmids\": [\"8663146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"BTG1 expression is maximal in G0/G1 phases and down-regulated as cells progress through G1; overexpression in NIH3T3 cells negatively regulates cell proliferation.\",\n      \"method\": \"Northern blot cell-cycle analysis, NIH3T3 transfection/proliferation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean overexpression with defined proliferative phenotype, foundational paper with 276 citations\",\n      \"pmids\": [\"1373383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTG1 (and BTG2) physically interact with mCaf1 (mouse CCR4-associated factor 1), a component of the CCR4 transcriptional regulatory complex; this interaction is mediated by box B of BTG1 and occurs both in vitro and in vivo in HeLa cells, suggesting BTG1 participates in transcriptional regulation of cell-cycle genes via the CCR4 complex.\",\n      \"method\": \"Yeast two-hybrid screening, GST pulldown, co-immunoprecipitation in HeLa cells, transient transfection assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP in vivo plus in vitro binding assay, domain mapping via mutagenesis, replicated by multiple labs\",\n      \"pmids\": [\"9712883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTG1 interacts with human hCAF-1 (hCCR4-associated factor 1); complex formation depends on phosphorylation of BTG1 at Ser-159 by cell-cycle kinases CDK2/cyclin E and CDK2/cyclin A (but not CDK4/cyclin D1 or CDC2/cyclin B); BTG1 and rCAF-1 co-immunoprecipitate and co-localize in the nucleus of contact-inhibited smooth muscle cells.\",\n      \"method\": \"Yeast two-hybrid, in vitro phosphorylation assay with recombinant kinases, site-directed mutagenesis (Ser159Ala), co-immunoprecipitation, immunohistochemistry, overexpression colony assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with mutagenesis plus reciprocal Co-IP in primary cells; multiple orthogonal methods\",\n      \"pmids\": [\"9820826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BTG1 physically associates with the homeodomain transcription factor Hoxb9 and enhances Hoxb9-mediated transcriptional activation; interaction facilitates Hoxb9 binding to DNA and is dependent on the activation domain of Hoxb9 and occurs in transfected cells.\",\n      \"method\": \"Yeast two-hybrid, GST pulldown, co-immunoprecipitation, transactivation assays, electrophoretic mobility shift assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal binding methods plus functional transcription assay with DNA binding confirmation\",\n      \"pmids\": [\"10617598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BTG1 interacts with hCAF1 and hPOP2 (human paralogs of yeast CCR4-associated factor 1) in vitro and in vivo; the BTG1/CAF1 interaction, likely via a CCR4-like complex, modulates estrogen receptor alpha (ERα)-mediated transcription; LXXLL nuclear receptor box motifs in BTG1 are required for regulation of ERα function.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, GST pulldown, transient transfection transcription assays, domain mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo binding with functional transcriptional readout; domain mapping by mutagenesis\",\n      \"pmids\": [\"11136725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BTG1 subcellular localization is controlled by multiple domains: the conserved B box drives nuclear localization, an overlapping nuclear export signal (NES) mediates cytoplasmic export, the N-terminal 43 residues reduce nuclear localization, an LxxLL motif promotes nuclear accumulation, and the A box inhibits nuclear localization. Nuclear-localized BTG1 mutants enhance myoblast withdrawal from the cell cycle and terminal differentiation, whereas cytoplasmic mutants do not.\",\n      \"method\": \"β-Galactosidase fusion localization assays, domain deletion mutagenesis, transient expression in myoblasts, cell cycle analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — systematic domain dissection with functional consequence on differentiation; multiple orthogonal constructs\",\n      \"pmids\": [\"11420681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FoxO3a directly transcriptionally activates BTG1 during erythroid differentiation; BTG1 in turn activates PRMT1 (protein arginine methyltransferase 1), and a domain of BTG1 required for PRMT1 binding is necessary for its inhibitory effect on erythroid progenitor outgrowth; inhibition of methyltransferase activity blocks erythroid maturation.\",\n      \"method\": \"Promoter reporter assays, retroviral overexpression in primary mouse bone marrow cells, colony formation assay, pharmacological inhibition of PRMT1\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter study, domain-function mapping, primary cell loss-of-function with defined phenotype, chemical inhibitor validation\",\n      \"pmids\": [\"14734530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BTG1 acts as a transcriptional coactivator of nuclear receptors (T3R, RAR) and the myogenic factor MyoD (CMD1); it directly interacts with T3R, RAR, and CMD1 via their transactivation domains and the A box/C-terminal region of BTG1; deletion of BTG1 interacting domains abrogates its stimulation of nuclear receptor and myogenic factor activity and abolishes its myogenic influence.\",\n      \"method\": \"Co-immunoprecipitation in cells, GST pulldown with in vitro-synthesized proteins, transactivation reporter assays, domain deletion mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP plus GST pulldown with domain mutagenesis and functional transcriptional assay\",\n      \"pmids\": [\"15674337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BTG1 promotes G1 cell cycle arrest in B lymphoma cells (WEHI-231) by binding PRMT1 via its box C region; this interaction is required for anti-IgM-induced growth inhibition; pharmacological inhibition of PRMT1 (AdOx) or PRMT1 siRNA knockdown abrogates BTG1-induced growth arrest; BTG1/PRMT1 activity induces arginine methylation of specific substrate proteins (p28 and p36).\",\n      \"method\": \"Retroviral overexpression, G1 phase FACS analysis, co-immunoprecipitation, PRMT1 siRNA knockdown, pharmacological inhibition, antibody detection of asymmetric methylarginine\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, genetic (siRNA) and pharmacological validation, domain-function requirement established\",\n      \"pmids\": [\"17466295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BTG1 controls glucocorticoid receptor (GR) autoinduction in ALL cells: loss of BTG1 by RNAi decimates GR expression and impairs GR-mediated transcription; re-expression of BTG1 restores GC sensitivity; PRMT1 (a BTG1 binding partner) is recruited to the GR gene promoter in a BTG1-dependent manner, implicating the BTG1/PRMT1 complex as a transcriptional coactivator at the GR locus.\",\n      \"method\": \"RNA interference knockdown, re-expression rescue, chromatin immunoprecipitation (ChIP) for PRMT1 at GR promoter, GC-sensitivity assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating BTG1-dependent PRMT1 recruitment, RNAi loss-of-function with defined transcriptional and sensitivity phenotype\",\n      \"pmids\": [\"20354172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Btg1 knockout in mice causes an initial burst of stem/progenitor cell proliferation in the dentate gyrus and subventricular zone followed by progressive depletion due to apoptosis (p53/p21 upregulation); Btg1-null progenitors exit the cell cycle after S-phase but undergo apoptosis within 5 days, indicating Btg1 maintains G1-to-S checkpoint control and quiescence of adult neural stem cells.\",\n      \"method\": \"Btg1 knockout mice, BrdU/EdU incorporation, immunofluorescence (p53, p21, cleaved caspase-3), neurosphere self-renewal assay, behavioral memory tests\",\n      \"journal\": \"Frontiers in neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple cellular phenotype readouts and mechanistic marker analysis\",\n      \"pmids\": [\"22969701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Btg1 regulates proliferation of cerebellar granule cell precursors selectively through cyclin D1; Btg1 knockout causes hyperplasia of the external granule layer with increased GCP proliferation; gain- and loss-of-function experiments in a GCP cell line confirm Btg1 controls proliferation via cyclin D1.\",\n      \"method\": \"Btg1 and double Btg1/Tis21 knockout mice, immunohistochemistry, gain/loss-of-function in GCP cell line, cyclin D1 protein analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO plus cell-line gain/loss-of-function with specific molecular target (cyclin D1) identified\",\n      \"pmids\": [\"26524254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTG1 promotes PRMT1-mediated methylation of ATF4 at arginine 239, positively modulating ATF4 transcriptional activity in the cellular stress response; BTG1 interacts with ATF4 and recruits PRMT1 to methylate it; loss of Btg1 in MEFs provides a survival advantage under stress conditions by deregulating ATF4-mediated gene expression.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (Arg239), in vitro methylation assay, Btg1 knockout MEFs, stress survival assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro methylation with specific residue identified, reciprocal Co-IP, KO cellular phenotype\",\n      \"pmids\": [\"26657730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTG1 reduces liver steatosis by suppressing ATF4 transcriptional activity, thereby decreasing SCD1 (stearoyl-CoA desaturase 1) expression; BTG1 abundance is regulated by an mTOR/S6K1/CREB pathway; BTG1 overexpression or knockdown reciprocally alters triglyceride accumulation in hepatocytes and in vivo in mice.\",\n      \"method\": \"Adenoviral BTG1 overexpression/knockdown in db/db and WT mice, BTG1 transgenic mice, SCD1 and ATF4 re-expression rescue experiments, reporter assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo and in vitro approaches with rescue epistasis establishing BTG1→ATF4→SCD1 pathway\",\n      \"pmids\": [\"27188441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTG1 regulates hepatic insulin sensitivity through c-Jun: BTG1 overexpression upregulates c-Jun expression by stimulating c-Jun promoter and retinoic acid receptor activities; adenoviral c-Jun knockdown blocks BTG1-improved insulin signaling in vitro and in vivo.\",\n      \"method\": \"Adenoviral overexpression/knockdown in mice and primary hepatocytes, reporter assays for c-Jun promoter, insulin tolerance tests, Western blot for insulin signaling\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by c-Jun knockdown rescue in vivo and in vitro; multiple orthogonal methods\",\n      \"pmids\": [\"26396236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BTG1 and BTG2 promote mRNA deadenylation and degradation in T cells to maintain quiescence; BTG1/2 deficiency results in increased poly(A) tail length, greater mRNA half-life, and global mRNA abundance increase that lowers the threshold for T cell activation; BTG1/2 double-knockout T cells show spontaneous proliferation and activation.\",\n      \"method\": \"BTG1/2 double-knockout mouse T cells, poly(A)-tail sequencing, mRNA half-life assays, global transcriptomics, T cell activation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean double-KO with poly(A) sequencing and mRNA stability assays; high-impact journal, multiple orthogonal methods\",\n      \"pmids\": [\"32165587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTG1's boxC motif mediates direct interaction with the first RRM domain of cytoplasmic poly(A) binding protein PABPC1; this boxC-PABPC1 interaction is necessary and sufficient within an APRO domain to stimulate mRNA deadenylation in cellulo and in vitro; the boxC motif is not required for BTG2 association with PRMT1.\",\n      \"method\": \"NMR spectroscopy, mutagenesis, in vitro deadenylation assay, co-immunoprecipitation, cell-based deadenylation reporter assay\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural data plus in vitro deadenylation assay plus mutagenesis; multiple orthogonal methods in single study\",\n      \"pmids\": [\"34060423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disease-associated BTG1 mutations found in non-Hodgkin lymphoma impair BTG1 interaction with CNOT7 and CNOT8 (Caf1 subunits of the CCR4-NOT deadenylase complex) and reduce its anti-proliferative activity, translational repression, and mRNA degradation functions.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, cell cycle assay, translational repression assay, mRNA degradation assay for 16 BTG1 variants\",\n      \"journal\": \"Leukemia & lymphoma\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic functional characterization of multiple disease mutants using orthogonal assays\",\n      \"pmids\": [\"33021411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTG1 is a physical partner of the scaffolding protein BCAR1; loss of BTG1 (knockout or patient-derived mutations) leads to overactivation of the BCAR1-RAC1 pathway, conferring increased B cell migration ability in vitro and in vivo and driving lymphoma dissemination.\",\n      \"method\": \"Co-immunoprecipitation, Btg1 knockout mouse lymphoma models (Bcl2-driven), in vitro and in vivo migration assays, SRC inhibitor (dasatinib) rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP establishing novel binding partner, in vivo disease model with pharmacological rescue\",\n      \"pmids\": [\"36375119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTG1 mutations in germinal center B cells disrupt a gatekeeper mechanism limiting B cell fitness during antibody affinity maturation by causing a small shift in MYC protein induction kinetics, converting GC B cells into supercompetitors that rapidly outstrip normal counterparts and progress to aggressive lymphoma.\",\n      \"method\": \"Primary human lymphoma analysis, new BTG1-mutant mouse models, competitive GC B cell assays, MYC protein kinetics measurement\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mouse genetic models with mechanistic readout (MYC kinetics), human lymphoma data, competitive in vivo B cell assays\",\n      \"pmids\": [\"36656933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Molecular dynamics simulations reveal that the α2-α4 interface of BTG1 undergoes conformational transitions between closed and open metastable states; DLBCL-associated mutations (Q36H, F40C, Q45P, E50K in α2; A83T, A84E in α4) either overstabilize one state or distort helix structure, disrupting the dynamic equilibrium required for productive interactions with binding partners.\",\n      \"method\": \"Atomistic molecular dynamics simulations, Markov state modeling of BTG1 wild-type and DLBCL mutants\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 4 — computational MD only, no experimental structural or biochemical validation in this study\",\n      \"pmids\": [\"35459639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BTG1 is a target of the triiodothyronine (T3)/cAMP myogenic signaling pathway; T3 or 8-Br-cAMP stimulate BTG1 nuclear accumulation in confluent myoblasts through increased nuclear import/retention; AP-1 activity represses BTG1 expression via an AP-1-like element in the BTG1 promoter; BTG1 overexpression mimics T3/cAMP myogenic influence by inhibiting proliferation and stimulating differentiation.\",\n      \"method\": \"Northern blot, transient transfection promoter assays, nuclear/cytoplasmic fractionation, overexpression in quail myoblasts\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — promoter mapping and subcellular fractionation with functional overexpression phenotype; single lab\",\n      \"pmids\": [\"10366433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTG1 interacts with PRMT1 in renal cell carcinoma cells; blocking PRMT1 activity inhibits BTG1-induced G0/G1 arrest and apoptosis, placing PRMT1 downstream of BTG1 in its antiproliferative mechanism in RCC.\",\n      \"method\": \"Co-immunoprecipitation, PRMT1 pharmacological inhibition, cell cycle FACS, apoptosis assay in 786-O RCC cells\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab Co-IP plus pharmacological inhibition linking BTG1-PRMT1 to defined phenotype\",\n      \"pmids\": [\"26622543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Btg1 and Btg2 are required for postnatal cardiomyocyte cell cycle arrest; Btg1/2 double knockout or knockdown mouse hearts show increased mitotic cardiomyocytes at P7; RNAseq of Btg1/2-depleted neonatal rat cardiomyocytes implicates BTG1/2 in inhibiting proliferation and modulating reactive oxygen species response pathways.\",\n      \"method\": \"Constitutive double KO mice, AAV9-mediated neonatal knockdown, siRNA in NRVM cultures, EdU/pHH3 staining, RNAseq\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO and KD with defined mitotic phenotype; RNAseq for pathway context; single lab\",\n      \"pmids\": [\"37062247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PUM2 (an RNA binding protein) binds directly to the 3'UTR of BTG1 mRNA to repress its expression; PUM2 knockdown increases BTG1 protein levels and suppresses glioblastoma proliferation and migration; BTG1 knockdown reverses PUM2 knockdown effects, placing BTG1 downstream of PUM2 in this regulatory axis.\",\n      \"method\": \"RNA pulldown assay, RNA immunoprecipitation, shRNA knockdown, CCK-8, migration/invasion assays\",\n      \"journal\": \"Cell structure and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — RNA pulldown and RIP establishing direct RNA-protein interaction, epistasis by rescue experiment; single lab\",\n      \"pmids\": [\"30787206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BTG1 suppresses β-catenin signaling by inhibiting formation of the β-catenin/TCF4 transcriptional complex, reducing downstream c-Myc and Cyclin D1 expression; in DLBCL, BTG1 is epigenetically upregulated by HDAC inhibitors, and BTG1-induced cell cycle arrest and autophagy are dependent on this suppression of β-catenin/TCF4.\",\n      \"method\": \"HDAC inhibitor treatment, BTG1 silencing/overexpression, co-immunoprecipitation for β-catenin/TCF4, reporter assays, xenograft mouse model\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP for complex disruption plus in vivo xenograft; single lab, novel finding\",\n      \"pmids\": [\"41950351\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTG1 is an antiproliferative transcriptional co-regulator that operates through three principal molecular mechanisms: (1) it directly binds and stimulates PRMT1 arginine methyltransferase activity (via its conserved boxC motif) to methylate substrates including ATF4 (at Arg239), thereby modulating stress responses and GR-mediated transcription; (2) it interacts with the CAF1/CCR4-NOT deadenylase complex (via boxA/boxB) and with cytoplasmic poly(A) binding protein PABPC1 (via boxC) to stimulate mRNA deadenylation and decay, maintaining cellular quiescence (especially in T cells); and (3) it acts as a transcriptional co-factor for nuclear receptors (T3R, RAR), myogenic factors (MyoD), homeobox proteins (Hoxb9), and by suppressing β-catenin/TCF4 complex assembly, collectively enforcing G0/G1 arrest and differentiation across multiple cell types.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nLooking at the corpus, I need to classify each paper:\n\n**EXCLUDE (alias collisions / off-target):**\n- Many gene2pubmed papers [1-30 in that section] are about platelet chemokines (CXCL4, CXCL7, beta-thromboglobulin, NAP-2), IL-8 receptors, G proteins, MGC cDNA projects, etc. — clearly not BTG1.\n- Paper [76] \"Targeting a novel circITCH/miR-421/BTG1 axis\" — this is about BTG1 as a target, but the primary subject is a circRNA. However, since it describes BTG1's role as a functional mediator, I'll keep it for the BTG1 mechanism.\n- Paper [75] Hyriopsis schlegelii BTG1 — mollusk BTG1, expression study only, no mechanistic data → EXCLUDE mechanistic extraction\n- Papers [42] AmphiTob — this is about Tob, not BTG1 → EXCLUDE\n\n**KEEP:** Papers [1-15, 17-18, 20-21, 23, 25-27, 29-30, 32-33, 36-37, 39, 43, 48, 52, 54, 59-62, 64-66, 72, 74, 77, 84] that describe BTG1 protein mechanisms.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"BTG1 was identified as an antiproliferative gene whose overexpression negatively regulates cell proliferation in NIH3T3 cells, and its expression is maximal in the G0/G1 phases of the cell cycle, decreasing as cells progress through G1.\",\n      \"method\": \"Transfection of NIH3T3 cells with BTG1 expression vector; Northern blot cell-cycle analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean overexpression with defined proliferation phenotype, single lab\",\n      \"pmids\": [\"1373383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BTG1 (and its paralog TIS21) physically interacts with PRMT1 (protein-arginine N-methyltransferase 1) via yeast two-hybrid, and GST-BTG1 fusion protein qualitatively and quantitatively modulates endogenous PRMT1 arginine methyltransferase activity in cell extracts, identifying PRMT1 as a functional effector of BTG1.\",\n      \"method\": \"Yeast two-hybrid screen; GST pulldown; in vitro methyltransferase activity assay with cell extracts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — yeast two-hybrid plus GST pulldown plus biochemical enzyme activity assay, foundational paper with 416 citations\",\n      \"pmids\": [\"8663146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTG1 and BTG2 physically interact with mCaf1 (mouse CCR4-associated factor 1, a component of the yeast CCR4 transcriptional regulatory complex) both in vitro and in vivo in HeLa cells; the conserved Box B domain of BTG1 is essential for this interaction, suggesting BTG proteins participate in transcriptional regulation of cell-cycle genes via the CCR4-NOT complex.\",\n      \"method\": \"Yeast two-hybrid screening; GST pulldown (protein-binding assay); co-immunoprecipitation in HeLa cells; deletion mutagenesis of Box B\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, yeast two-hybrid, in vitro pulldown, and mutagenesis in single study with 125 citations\",\n      \"pmids\": [\"9712883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTG1 interaction with hCAF1 (human CCR4-associated factor 1) requires phosphorylation of Ser-159 on BTG1 by CDK2/cyclin E or CDK2/cyclin A (but not CDK4/cyclin D1 or CDC2/cyclin B); an Ala-159 mutant fails to interact with hCAF1 in yeast. In contact-inhibited smooth muscle cells, BTG1 and rCAF1 co-localize in the nucleus and co-immunoprecipitate.\",\n      \"method\": \"Yeast two-hybrid with phosphorylation-site mutants; in vitro kinase assay with purified CDKs; co-immunoprecipitation from cell extracts; immunohistochemistry; cell synchrony experiments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro kinase assay identifying specific CDKs, mutagenesis, and co-IP validation\",\n      \"pmids\": [\"9820826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BTG1 and BTG2 physically interact with the homeodomain transcription factor Hoxb9 via yeast two-hybrid and in vitro binding, and enhance Hoxb9-mediated transcription in transfected cells; the Hoxb9·BTG2 complex forms on a Hoxb9-responsive DNA target, facilitating Hoxb9 DNA binding. The transcriptional activation is dependent on the N-terminal activation domain of Hoxb9.\",\n      \"method\": \"Yeast two-hybrid; GST pulldown; transient transfection transcription assays; electrophoretic mobility shift assay (EMSA)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Y2H, pulldown, transcription assay, EMSA) in single study, 122 citations\",\n      \"pmids\": [\"10617598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BTG1 and BTG2 interact with both hCAF1 and hPOP2 (human paralogs of the CCR4-associated factor). Two LXXLL nuclear receptor box motifs in BTG1 and BTG2 are required for regulation of estrogen receptor alpha (ERα)-mediated transcription; BTG proteins can act as both positive and negative regulators of ERα function, likely through a CCR4-like complex.\",\n      \"method\": \"Yeast two-hybrid; GST pulldown; co-immunoprecipitation; transient transfection luciferase transcription assays; deletion/mutagenesis of LXXLL motifs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including mutagenesis and transcription assays, 108 citations\",\n      \"pmids\": [\"11136725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The subcellular localization of BTG1 is controlled by multiple domains: the conserved B box mediates nuclear localization, a functional Nuclear Export Signal (NES) overlaps the B box, the first 43 N-terminal amino acids reduce nuclear accumulation, an LxxLL motif favors nuclear accumulation, and the A box inhibits nuclear localization. A nuclear-localized BTG1 mutant enhances myoblast withdrawal from the cell cycle and terminal differentiation, whereas a cytoplasmic-only mutant does not, establishing that BTG1 myogenic activity operates from the nucleus.\",\n      \"method\": \"Beta-galactosidase fusion localization assays; domain deletion/mutation constructs; transient expression in myoblasts with cell cycle and differentiation readouts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence via domain mutagenesis\",\n      \"pmids\": [\"11420681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FoxO3a directly targets the BTG1 promoter and induces BTG1 expression during erythroid differentiation. BTG1 expression in primary mouse bone marrow cells blocks erythroid colony outgrowth, and this anti-proliferative effect requires the domain of BTG1 that binds PRMT1. Inhibition of methyltransferase activity blocks erythroid maturation, placing the BTG1/PRMT1 axis as a downstream effector of FoxO3a in controlling erythroid expansion.\",\n      \"method\": \"Promoter-reporter assays; retroviral overexpression in primary bone marrow cells; colony formation assay; pharmacological inhibition of methyltransferase; BTG1 domain deletion mutants\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including primary cell assays, domain mutants, and pharmacological inhibition, 142 citations\",\n      \"pmids\": [\"14734530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BTG1 overexpression in cultured endothelial cells augments tube formation and cell migration on Matrigel, while antisense BTG1 inhibits network formation; BTG1 mRNA is up-regulated in tube-forming endothelial cells and by TGF-β, defining a pro-angiogenic role for BTG1 in this cellular context.\",\n      \"method\": \"Antisense and sense BTG1 overexpression in endothelial cells; Matrigel tube formation assay; cell migration assay; neutralizing antibody against TGF-β\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — gain- and loss-of-function with specific angiogenic phenotypic readout, single lab\",\n      \"pmids\": [\"15033446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BTG1 directly interacts with thyroid hormone receptor (T3R) and all-trans retinoic acid receptor (RAR) (but not RXRα or PPARγ), and with the myogenic factor avian MyoD (CMD1), as shown by co-immunoprecipitation in cells and GST pulldown with in vitro-synthesized proteins. These interactions are mediated by the transactivation domain of each transcription factor and the A box plus C-terminal region of BTG1. Deletion of BTG1 interacting domains abolishes its ability to stimulate nuclear receptor and CMD1 activity and its myogenic influence, establishing BTG1 as a transcriptional coactivator during myoblast differentiation.\",\n      \"method\": \"Co-immunoprecipitation in cultured myoblasts; GST pulldown with in vitro-translated proteins; transcriptional reporter assays; BTG1 deletion mutagenesis; myoblast differentiation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro pulldown with in vitro-synthesized proteins plus cellular Co-IP plus functional mutagenesis, 57 citations\",\n      \"pmids\": [\"15674337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BTG1 and BTG2 bind PRMT1 via their Box C region; this interaction is required for anti-IgM-induced G1 growth arrest in WEHI-231 B lymphoma cells. Pharmacological inhibition of arginine methyltransferase (AdOx) or siRNA knockdown of PRMT1 abrogates BTG1/BTG2-induced growth inhibition. Anti-IgM stimulation induces PRMT1-dependent arginine methylation of a 36-kDa protein substrate within 1-2 hours.\",\n      \"method\": \"Retroviral overexpression; flow cytometry (cell cycle); pharmacological inhibition with AdOx; siRNA knockdown of PRMT1; immunoprecipitation with anti-asymmetric dimethylarginine antibody; BTG1 domain mutagenesis (Box C)\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis, siRNA knockdown, pharmacological inhibition all converge on PRMT1 as effector of BTG1 growth arrest, 31 citations\",\n      \"pmids\": [\"17466295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BTG1 is a key determinant of glucocorticoid (GC) responsiveness in acute lymphoblastic leukemia: BTG1 knockdown causes GC resistance by reducing glucocorticoid receptor (GR) expression and impairing GR-mediated transcription, while BTG1 re-expression restores GC sensitivity by potentiating GC-induced GR autoinduction. PRMT1, a BTG1-binding partner, is recruited to the GR gene promoter in a BTG1-dependent manner, implicating the BTG1/PRMT1 complex as a transcriptional coactivator of GR.\",\n      \"method\": \"RNA interference (shRNA); GR expression rescue experiments; chromatin immunoprecipitation (ChIP) of PRMT1 at GR promoter; luciferase reporter assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNAi with defined molecular mechanism (GR autoinduction), ChIP demonstrating PRMT1 recruitment at GR promoter in BTG1-dependent manner, 66 citations\",\n      \"pmids\": [\"20354172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Btg1 knockout mice show transient early hyperproliferation followed by progressive depletion of adult stem and progenitor cells in the dentate gyrus and subventricular zone. Adult Btg1-null stem/progenitor cells exit the cell cycle after S phase, upregulate p53 and p21, and undergo apoptosis within 5 days, indicating that Btg1 is required for maintaining adult neural stem cell quiescence and self-renewal.\",\n      \"method\": \"Btg1 knockout mouse generation; BrdU/EdU incorporation; immunofluorescence for p53, p21, activated caspase-3; neurosphere self-renewal assay; contextual memory behavioral tests\",\n      \"journal\": \"Frontiers in neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with specific molecular (p53/p21 upregulation) and cellular (apoptosis, cell cycle exit) phenotype, 59 citations\",\n      \"pmids\": [\"22969701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Btg1 regulates cerebellar granule precursor (GCP) proliferation selectively through cyclin D1: Btg1 knockout causes increased GCP proliferation and EGL hyperplasia, while gain- and loss-of-function experiments in a GCP cell line confirm that Btg1 controls proliferation via cyclin D1. Combined Btg1/Tis21 double knockout reveals additive defects in proliferation and migration. Btg1-null mice display permanent increase in adult cerebellar volume and impaired motor coordination.\",\n      \"method\": \"Btg1 single and double (Btg1/Tis21) knockout mice; BrdU incorporation; immunohistochemistry; gain- and loss-of-function in GCP cell line with cyclin D1 readout; behavioral motor testing\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice plus cell-line gain/loss-of-function with specific molecular mechanism (cyclin D1), replicated in vivo and in vitro\",\n      \"pmids\": [\"26524254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTG1 interacts with PRMT1 in renal cell carcinoma cells; BTG1 overexpression induces G0/G1 arrest and apoptosis in 786-O cells, and pharmacological blocking of PRMT1 activity inhibits BTG1 function, demonstrating that BTG1's anti-proliferative and pro-apoptotic effects in RCC require PRMT1 activity.\",\n      \"method\": \"Co-immunoprecipitation; BTG1 overexpression with flow cytometry (cell cycle, apoptosis); PRMT1 inhibitor treatment\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Co-IP and pharmacological inhibition with defined phenotype, single lab\",\n      \"pmids\": [\"26622543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTG1 interacts with ATF4 and recruits PRMT1 to methylate ATF4 at arginine residue 239, positively modulating ATF4 transcriptional activity. Loss of Btg1 in MEFs provides a survival advantage under stress conditions (hypoxia, nutrient limitation) by altering ATF4-mediated stress responses. Loss of Btg1 also enhances stress adaptation of bone marrow-derived B-cell progenitors.\",\n      \"method\": \"Btg1 knockout MEFs and B-cell progenitors; co-immunoprecipitation of BTG1-ATF4; in vitro methylation assay identifying Arg-239 as PRMT1 target; cell survival assays under stress; luciferase reporter assays for ATF4 activity\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — co-IP plus in vitro methylation with site identification plus KO cells with defined stress-survival phenotype, 34 citations\",\n      \"pmids\": [\"26657730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTG1 overexpression in db/db obese mice ameliorates liver steatosis, while BTG1 knockdown induces steatosis in wild-type mice. BTG1 suppresses ATF4 activity to inhibit SCD1 (stearoyl-CoA desaturase 1) gene expression, thereby reducing hepatic triglyceride accumulation. BTG1 expression itself is regulated by the mTOR/S6K1/CREB pathway.\",\n      \"method\": \"Adenovirus-mediated overexpression/knockdown in vivo; BTG1 transgenic mice on high-carbohydrate diet; ATF4 overexpression rescue; SCD1 knockdown epistasis; hepatic lipid quantification\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain- and loss-of-function with epistasis (ATF4 rescue, SCD1 knockdown) establishing pathway position, 32 citations\",\n      \"pmids\": [\"27188441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTG1 regulates hepatic insulin sensitivity via upregulation of c-Jun expression: BTG1 overexpression improves insulin signaling in vitro and in vivo (db/db mice), while BTG1 knockdown impairs it. c-Jun knockdown blocks the BTG1-mediated improvement in insulin sensitivity. BTG1 promotes c-Jun expression by stimulating c-Jun and retinoic acid receptor transcriptional activities. Hepatic BTG1 is increased by leucine deprivation through the mTOR/S6K1 pathway.\",\n      \"method\": \"Adenovirus-mediated BTG1 overexpression/knockdown in vivo and in vitro; BTG1 transgenic mice; insulin tolerance and glucose tolerance tests; c-Jun knockdown epistasis; luciferase reporter assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain/loss-of-function with defined epistasis (c-Jun knockdown), 15 citations\",\n      \"pmids\": [\"26396236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BTG1 and BTG2 promote mRNA deadenylation and decay to maintain T cell quiescence. BTG1/2-deficient T cells show globally increased mRNA abundance due to lengthened poly(A) tails and greater mRNA half-life, reducing the activation threshold and causing spontaneous T cell activation and proliferation. BTG1/2 thus function as regulators of the deadenylation machinery to control quiescence.\",\n      \"method\": \"BTG1/BTG2 double-knockout T cells; RNA-seq; poly(A) tail length sequencing; mRNA half-life measurement; T cell activation and proliferation assays\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — double KO with genome-wide mRNA abundance, poly(A) tail and half-life measurements plus defined cellular phenotype, 142 citations\",\n      \"pmids\": [\"32165587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The Box C motif in BTG1 (and BTG2) is necessary and sufficient for interaction with the first RRM domain of cytoplasmic poly(A) binding protein PABPC1, and this interaction—demonstrated by NMR and mutagenesis—endows the APRO domain with the ability to stimulate mRNA deadenylation both in cellulo and in vitro. Unexpectedly, Box C is not required for BTG2 interaction with PRMT1.\",\n      \"method\": \"NMR spectroscopy; mutational analysis (Box C deletions/mutations); GST pulldown and co-immunoprecipitation; in vitro and cellular deadenylation assays\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure plus mutagenesis plus functional deadenylation assays in vitro and in cellulo\",\n      \"pmids\": [\"34060423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disease-associated BTG1 mutations found in non-Hodgkin lymphoma impair interaction with CNOT7 and CNOT8 (the Caf1 catalytic subunit of the CCR4-NOT deadenylase complex) and reduce BTG1 anti-proliferative activity, cell cycle inhibition, translational repression, and mRNA degradation activity, establishing loss of CCR4-NOT engagement as a mechanism of BTG1 inactivation in lymphoma.\",\n      \"method\": \"In silico selection of 16 BTG1 variants; protein-protein interaction assays with CNOT7/CNOT8; cell cycle assays; translational repression assays; mRNA degradation assays\",\n      \"journal\": \"Leukemia & lymphoma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple functional assays with multiple mutants but single lab, 11 citations\",\n      \"pmids\": [\"33021411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTG1 mutations in germinal center B cells disrupt a gatekeeper mechanism limiting B cell fitness during affinity maturation, converting GC B cells into 'supercompetitors' that outstrip wild-type counterparts. This competitive advantage is conferred by a small shift in MYC protein induction kinetics and leads to aggressive invasive lymphomas. BTG1 mutations are enriched in MCD/C5 DLBCL subtype.\",\n      \"method\": \"Primary human lymphoma genomics; new mouse models of BTG1 mutation; competitive GC B cell assays; MYC induction kinetics measurement; in vivo lymphoma models\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mouse models plus human lymphoma data plus mechanistic link to MYC kinetics, 36 citations\",\n      \"pmids\": [\"36656933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTG1 inactivation accelerates lymphoproliferative disease driven by BCL2 overexpression. BTG1 directly interacts with the scaffolding protein BCAR1, and BTG1 deletion or DLBCL-associated BTG1 mutations cause overactivation of the BCAR1-RAC1 pathway, conferring increased B cell migration ability in vitro and in vivo. This is targetable with the SRC inhibitor dasatinib.\",\n      \"method\": \"Btg1 knockout mouse crossed onto Bcl2-overexpressing background; co-immunoprecipitation (BTG1-BCAR1); RAC1 activation assay; in vitro migration assays; in vivo dissemination models; dasatinib treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifying novel partner BCAR1, in vivo and in vitro functional validation with pharmacological rescue, 8 citations\",\n      \"pmids\": [\"36375119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Molecular dynamics simulations reveal that the α2-α4 interface of BTG1 undergoes conformational transitions between 'closed' and 'open' metastable states, and this interface serves as a binding hotspot for cellular partners. DLBCL mutations (Q36H, F40C, Q45P, E50K in α2; A83T, A84E in α4) either overstabilize one state or distort the helices, disrupting the dynamic equilibrium required for productive interactions with binding partners.\",\n      \"method\": \"Atomistic molecular dynamics simulations; Markov state modeling; structural analysis of WT and DLBCL mutants\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation\",\n      \"pmids\": [\"35459639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Btg1 and Btg2 contribute to postnatal cardiomyocyte cell cycle arrest: double knockout (DKO) mice show increased mitotic cardiomyocytes at postnatal day 7 but not day 30. AAV9-mediated double knockdown confirms increased EdU+ cardiomyocytes at P7. siRNA-mediated knockdown in neonatal rat ventricular myocytes increases EdU+ cardiomyocytes without binucleation or ploidy increase. RNAseq supports roles in inhibiting proliferation and modulating ROS response pathways.\",\n      \"method\": \"Btg1/2 double knockout mice; AAV9-shRNA knockdown; siRNA knockdown in NRVMs; EdU/pHH3 incorporation assays; RNAseq\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — double KO and knockdown with specific mitotic phenotype, multiple in vivo and in vitro approaches\",\n      \"pmids\": [\"37062247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Targeted deletion of Btg1 and Btg2 causes homeotic transformation of the axial skeleton (posterior transformation of cervical, thoracic, and lumbar vertebrae), with Btg1 and Btg2 acting synergistically. These phenotypes are consistent with roles as modulators of Hox transcription factor function in vivo.\",\n      \"method\": \"Btg1 single KO, Btg2 single KO, and Btg1/Btg2 double KO mice; skeletal preparation and analysis of vertebral identity\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via double KO establishing synergistic role in Hox-dependent axial patterning\",\n      \"pmids\": [\"26218146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTG1 expression in developing limb digit blastemas negatively influences cartilage differentiation in micromass cultures, accompanied by upregulation of Ccn1, Scleraxis, and PTHrP. BTG1 overexpression upregulates retinoic acid and thyroid hormone receptors but its connective tissue differentiation influence appears independent of these nuclear receptor signaling pathways in this context.\",\n      \"method\": \"In situ hybridization in developing limb; gain- and loss-of-function in micromass cultures; qRT-PCR for target genes\",\n      \"journal\": \"Cell and tissue research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, limited mechanistic follow-up beyond target gene expression changes\",\n      \"pmids\": [\"26662056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Chidamide (HDAC inhibitor) identifies BTG1 as a target gene in resistant B-cell lymphoma: ChIP analysis shows BTG1 is epigenetically regulated by histone deacetylase activity. BTG1 controls autophagy in rituximab/chemotherapy-resistant lymphoma cells, contributing to chidamide-induced cell death.\",\n      \"method\": \"RNA-seq; chromatin immunoprecipitation (ChIP); autophagy assays; cell death assays in resistant lymphoma cells and mouse xenograft model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP demonstrating epigenetic regulation plus functional autophagy assays, single lab\",\n      \"pmids\": [\"34599153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"BTG1 is epigenetically upregulated by HDAC inhibition in DLBCL cells and suppresses β-catenin signaling by inhibiting formation of the β-catenin/TCF4 transcriptional complex, reducing downstream targets c-Myc and Cyclin D1. BTG1 is necessary and sufficient for HDAC inhibitor-induced cell cycle arrest and autophagy in DLBCL. In vivo antitumor efficacy of HDAC inhibition depends on the BTG1/β-catenin axis.\",\n      \"method\": \"BTG1 overexpression and siRNA knockdown; co-immunoprecipitation of β-catenin/TCF4 complex; luciferase reporter for β-catenin/TCF4 activity; DLBCL xenograft mouse model; cell cycle and autophagy assays\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus in vivo epistasis but very recently published (0 citations)\",\n      \"pmids\": [\"41950351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Loss of Btg1 in medulloblastoma (Ptch1+/- background) increases apoptosis of neoplastic cerebellar granule precursors (marked by activated caspase-3) and is associated with increased PRMT1 protein expression. Pro-apoptotic gene BAD is a PRMT1 target, suggesting increased PRMT1 activity mediates the apoptosis increase in Btg1-null tumors. Btg1 ablation also doubles CD15+ tumor stem cells in medulloblastoma.\",\n      \"method\": \"Btg1/Ptch1 double mutant mice; immunostaining for activated caspase-3 and PRMT1; CD15 staining for tumor stem cells; analysis of BAD as PRMT1 target\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo genetic model with mechanistic link to PRMT1/BAD pathway, but indirect evidence for PRMT1 mediating apoptosis\",\n      \"pmids\": [\"32231994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BTG1 deficiency enhances the self-renewal of ETV6-RUNX1-positive fetal liver hematopoietic progenitors, and combined ETV6-RUNX1 expression with BTG1 loss drives upregulation of BCL6 and suppression of its targets p19Arf and Tp53. BTG1 thus limits BCL6 expression downstream of ETV6-RUNX1, acting as a tumor suppressor by restraining a BCL6-driven self-renewal program.\",\n      \"method\": \"Btg1-deficient mouse fetal liver hematopoietic progenitors; ETV6-RUNX1 retroviral expression; serial replating/self-renewal assays; gene expression analysis of BCL6, p19Arf, Tp53; ectopic BCL6 expression rescue\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in primary cells with defined pathway (BCL6 upregulation) and downstream target validation\",\n      \"pmids\": [\"29408281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BTG1 overexpression in quail myoblasts mimics triiodothyronine (T3) and cAMP myogenic influences: it inhibits myoblast proliferation by increasing cell cycle withdrawal and stimulates terminal differentiation. T3 and cAMP stimulate BTG1 nuclear accumulation in confluent myoblasts. AP-1 activity represses BTG1 expression via an AP-1-like sequence in the BTG1 promoter, explaining low BTG1 levels in proliferating cells.\",\n      \"method\": \"Transient transfection and stable overexpression in quail myoblasts; cell cycle analysis; differentiation assays; promoter-reporter assays with AP-1 site mutation; subcellular localization by immunofluorescence\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with proliferation/differentiation phenotype plus promoter mechanism via mutagenesis\",\n      \"pmids\": [\"10366433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PUM2 (an RNA-binding protein) binds directly to the BTG1 3'UTR as demonstrated by RNA pulldown and RNA immunoprecipitation, repressing BTG1 expression at the post-transcriptional level. PUM2 knockdown in glioblastoma cells suppresses proliferation and migration, and these effects are reversed by BTG1 knockdown, placing BTG1 as a functional downstream target of PUM2-mediated post-transcriptional repression.\",\n      \"method\": \"RNA pulldown assay; RNA immunoprecipitation (RIP); shRNA knockdown of PUM2 and BTG1; CCK-8 proliferation assay; migration/invasion assay\",\n      \"journal\": \"Cell structure and function\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RNA pulldown and RIP demonstrating direct 3'UTR binding, with functional epistasis\",\n      \"pmids\": [\"30787206\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTG1 is an antiproliferative transcriptional cofactor that operates primarily through two major biochemical mechanisms: (1) interaction with PRMT1 via its Box C motif to modulate arginine methylation of substrates including ATF4 (Arg-239) and to coactivate nuclear receptors (GR, ERα, T3R, RAR) and myogenic factors, thereby regulating differentiation and stress responses; and (2) interaction with the CAF1/CCR4-NOT deadenylase complex (via Box A/B domains) and with PABPC1 (via Box C) to promote mRNA deadenylation and decay, maintaining cellular quiescence—most clearly demonstrated in T cells. BTG1 also interacts with BCAR1 to suppress RAC1-mediated B cell migration, interacts with Hoxb9 to coactivate Hox-dependent transcription, and controls neural stem cell quiescence and cardiomyocyte cell cycle arrest through cyclin D1-dependent mechanisms; disease-associated mutations in DLBCL disrupt the α2-α4 binding interface and impair CAF1/CNOT7/CNOT8 engagement, abolishing anti-proliferative activity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BTG1 is an antiproliferative co-regulator that enforces cellular quiescence and differentiation by coupling transcriptional control with post-transcriptional mRNA decay. BTG1 stimulates PRMT1 arginine methyltransferase activity through its conserved boxC motif, directing methylation of substrates such as ATF4 (at Arg239) to modulate stress responses, glucocorticoid receptor autoinduction, and cell-cycle arrest in diverse cell types including B lymphocytes, erythroid progenitors, and neural stem cells [PMID:8663146, PMID:17466295, PMID:20354172, PMID:26657730]. Concurrently, BTG1 interacts via its boxA/boxB domains with the CAF1/CCR4-NOT deadenylase complex and via boxC with PABPC1 to stimulate mRNA deadenylation, thereby globally limiting mRNA abundance and maintaining T cell quiescence [PMID:9712883, PMID:32165587, PMID:34060423]. BTG1 also functions as a transcriptional coactivator for nuclear receptors (T3R, RAR, ERα), Hoxb9, and MyoD, and suppresses β-catenin/TCF4 complex formation; loss-of-function mutations in BTG1 are recurrent in diffuse large B cell lymphoma and non-Hodgkin lymphoma, where they derestrict MYC induction kinetics to create supercompetitor germinal-center B cells that drive lymphomagenesis [PMID:15674337, PMID:36656933, PMID:33021411].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing BTG1 as a cell-cycle-regulated antiproliferative gene answered the foundational question of whether this newly cloned gene had a role in growth control.\",\n      \"evidence\": \"Northern blot cell-cycle profiling and NIH3T3 overexpression proliferation assay\",\n      \"pmids\": [\"1373383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of growth inhibition unknown\", \"No binding partners identified\", \"No in vivo loss-of-function data\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Discovery that BTG1 physically binds and stimulates PRMT1 enzymatic activity provided the first molecular effector mechanism for its antiproliferative function.\",\n      \"evidence\": \"Yeast two-hybrid, GST pulldown, in vitro methyltransferase assay\",\n      \"pmids\": [\"8663146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates of PRMT1 in BTG1-regulated contexts not identified\", \"Whether PRMT1 activation is required for growth arrest not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of CAF1/CCR4-NOT complex as a BTG1 interactor, with phosphorylation at Ser-159 by CDK2 regulating the interaction, revealed a second effector axis and linked BTG1 to cell-cycle kinase input.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, in vitro kinase assays with site-directed mutagenesis\",\n      \"pmids\": [\"9712883\", \"9820826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of CAF1 interaction on mRNA metabolism not yet demonstrated\", \"Whether Ser-159 phosphorylation triggers BTG1 degradation or dissociation unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that BTG1 enhances Hoxb9 DNA binding and transcriptional activation established BTG1 as a bona fide transcriptional co-regulator beyond simple growth arrest.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, EMSA, transactivation reporter assays\",\n      \"pmids\": [\"10617598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous genomic targets of BTG1-Hoxb9 not mapped\", \"Relevance to developmental patterning not tested in vivo\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Domain dissection showing that nuclear localization is required for BTG1's differentiation-promoting activity, and that BTG1 coactivates nuclear receptors (ERα, T3R, RAR) and MyoD, unified its transcriptional cofactor functions with its antiproliferative role.\",\n      \"evidence\": \"β-galactosidase fusion localization, domain deletion mutagenesis in myoblasts, Co-IP and reporter assays with nuclear receptors\",\n      \"pmids\": [\"11420681\", \"11136725\", \"15674337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTG1 is recruited to chromatin at target gene promoters not shown\", \"Structural basis of nuclear receptor interaction unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placing BTG1 downstream of FoxO3a and upstream of PRMT1 in erythroid differentiation established a linear signaling axis (FoxO3a→BTG1→PRMT1) with physiological relevance in hematopoiesis.\",\n      \"evidence\": \"Promoter reporter assays, retroviral overexpression in primary bone marrow, colony assay, pharmacological PRMT1 inhibition\",\n      \"pmids\": [\"14734530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PRMT1 substrates relevant to erythroid maturation not identified\", \"Whether BTG1 is required (loss-of-function) for normal erythropoiesis in vivo not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Genetic and pharmacological evidence that PRMT1 activity is required for BTG1-mediated G1 arrest in B lymphoma cells established the BTG1-PRMT1 axis as necessary — not merely sufficient — for growth suppression.\",\n      \"evidence\": \"PRMT1 siRNA and AdOx inhibitor in WEHI-231 cells with retroviral BTG1, FACS cell-cycle analysis\",\n      \"pmids\": [\"17466295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of p28/p36 methylated substrates unknown\", \"Whether this mechanism operates in normal B cells unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"ChIP demonstration that BTG1 recruits PRMT1 to the glucocorticoid receptor promoter in ALL cells revealed a chromatin-level mechanism by which BTG1 loss causes glucocorticoid resistance.\",\n      \"evidence\": \"RNAi knockdown, re-expression rescue, ChIP for PRMT1 at GR promoter, GC-sensitivity assays in ALL cells\",\n      \"pmids\": [\"20354172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTG1 itself occupies the GR promoter not shown\", \"Genome-wide extent of BTG1/PRMT1 co-recruitment unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Btg1 knockout mice revealed that BTG1 maintains adult neural stem cell quiescence: its loss causes transient hyperproliferation followed by p53/p21-dependent apoptotic depletion, demonstrating an in vivo quiescence gatekeeper role.\",\n      \"evidence\": \"Btg1 KO mice, BrdU/EdU pulse-chase, cleaved caspase-3 and p53/p21 immunofluorescence, neurosphere assays\",\n      \"pmids\": [\"22969701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular effector (PRMT1 vs. CAF1 axis) mediating stem cell quiescence not dissected\", \"Whether the phenotype is cell-autonomous not formally tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of cyclin D1 as the downstream target of Btg1 in cerebellar granule cell precursors, and the BTG1→c-Jun/RAR axis controlling hepatic insulin sensitivity, expanded BTG1's physiological roles to brain development and metabolic regulation.\",\n      \"evidence\": \"Btg1 KO and double Btg1/Tis21 KO mice for cerebellum; adenoviral gain/loss-of-function with epistasis (c-Jun KD) in mice and hepatocytes\",\n      \"pmids\": [\"26524254\", \"26396236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTG1-cyclin D1 regulation is transcriptional or post-transcriptional not resolved\", \"Relative contribution of PRMT1 vs. deadenylation in hepatic function unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that BTG1 recruits PRMT1 to methylate ATF4 at Arg239, and that BTG1 suppresses hepatic steatosis via the ATF4→SCD1 axis, identified the first specific methylation site on a defined substrate and linked the BTG1-PRMT1 pathway to lipid metabolism.\",\n      \"evidence\": \"In vitro methylation with Arg239 mutagenesis, Co-IP, Btg1 KO MEFs, adenoviral gain/loss-of-function in db/db mice\",\n      \"pmids\": [\"26657730\", \"27188441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Arg239 methylation alters ATF4 stability, DNA binding, or cofactor recruitment not determined\", \"Full spectrum of BTG1/PRMT1-methylated substrates unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"BTG1/BTG2 double-knockout T cells revealed that the BTG proteins are major enforcers of mRNA deadenylation-dependent quiescence: their loss globally extends poly(A) tails, increases mRNA half-life, and lowers the activation threshold, resolving a long-standing question about the physiological function of the BTG-CAF1 interaction.\",\n      \"evidence\": \"Double KO mouse T cells, poly(A)-tail sequencing, mRNA half-life measurement, global transcriptomics\",\n      \"pmids\": [\"32165587\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of BTG1 vs. BTG2 not individually dissected\", \"Whether deadenylation function operates independently of PRMT1 in T cells not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Systematic characterization of lymphoma-associated BTG1 mutations showed they disrupt CNOT7/CNOT8 interaction and impair antiproliferative, translational repression, and mRNA degradation functions, directly linking disease mutations to the deadenylation effector axis.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, cell cycle and mRNA degradation assays for 16 BTG1 variants\",\n      \"pmids\": [\"33021411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether these mutations also affect PRMT1 binding not systematically tested\", \"In vivo pathogenic consequence of individual mutations not modeled\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"NMR-resolved interaction between the BTG1 boxC motif and PABPC1-RRM1 provided the structural basis for BTG1-stimulated deadenylation, showing that PABPC1 recruitment is the proximal trigger for CCR4-NOT activation on mRNA.\",\n      \"evidence\": \"NMR spectroscopy, mutagenesis, in vitro and cell-based deadenylation assays\",\n      \"pmids\": [\"34060423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic-resolution structure of the BTG1-PABPC1-CCR4-NOT ternary complex not available\", \"Whether boxC engages PRMT1 and PABPC1 competitively or sequentially unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that BTG1 restrains BCAR1-RAC1 signaling to limit B cell migration, and that BTG1 mutations shift MYC induction kinetics to create germinal center supercompetitors, provided two complementary mechanisms explaining why BTG1 loss drives lymphomagenesis.\",\n      \"evidence\": \"Co-IP for BTG1-BCAR1, Btg1 KO Bcl2 mouse lymphoma model with dasatinib rescue; BTG1-mutant GC B cell competitive assays, MYC protein kinetics\",\n      \"pmids\": [\"36375119\", \"36656933\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BTG1 restrains BCAR1 biochemically (direct inhibition vs. scaffold sequestration) not resolved\", \"Whether MYC kinetics shift depends on deadenylation or PRMT1 axis unknown\", \"Therapeutic targeting of BTG1-loss vulnerabilities not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) whether the PRMT1-dependent and CAF1/deadenylation-dependent functions operate in parallel or are coordinated, (2) the full spectrum of PRMT1 substrates methylated in a BTG1-dependent manner, (3) the structural basis of BTG1 interaction with multiple transcription factors, and (4) how BTG1 boxC partitions between PRMT1 and PABPC1 binding.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No reconstituted system testing both PRMT1 and deadenylase functions simultaneously\", \"Genome-wide chromatin occupancy map for BTG1 lacking\", \"No high-resolution structure of full-length BTG1 in complex with any partner\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 9, 13, 17]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 5, 8, 10, 14, 15, 26]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [10, 13, 17, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 6, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 9, 11, 12, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 8, 10, 15]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [16, 17, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [16, 20]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 12]}\n    ],\n    \"complexes\": [\n      \"CCR4-NOT deadenylase complex\"\n    ],\n    \"partners\": [\n      \"PRMT1\",\n      \"CNOT7\",\n      \"CNOT8\",\n      \"PABPC1\",\n      \"BCAR1\",\n      \"ATF4\",\n      \"HOXB9\",\n      \"RARA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"BTG1 is an antiproliferative transcriptional cofactor and mRNA decay regulator that enforces cellular quiescence and controls differentiation across multiple lineages. It exerts its functions through two principal biochemical axes: interaction with PRMT1 via its Box C motif to modulate arginine methylation of substrates such as ATF4 (Arg-239) and to coactivate nuclear receptors (GR, ERα, T3R, RAR) and myogenic factors, thereby linking cell cycle arrest to transcriptional programs in erythroid, B cell, hepatic, and muscle differentiation contexts [PMID:8663146, PMID:15674337, PMID:20354172, PMID:26657730]; and interaction with the CAF1/CCR4-NOT deadenylase complex (via Box A/B domains) and PABPC1 (via Box C), promoting mRNA deadenylation and decay that maintains quiescence — most clearly demonstrated by globally increased mRNA stability and spontaneous T cell activation in BTG1/2 double-knockout T cells [PMID:32165587, PMID:34060423]. Loss-of-function BTG1 mutations recurrent in diffuse large B cell lymphoma disrupt the α2–α4 binding interface required for CAF1/CNOT7/CNOT8 engagement, abolishing antiproliferative activity and converting germinal center B cells into supercompetitors with altered MYC induction kinetics that drive aggressive lymphomagenesis [PMID:33021411, PMID:36656933]. In vivo, Btg1 deletion causes hyperproliferation followed by stem/progenitor depletion in adult neural niches, increased cardiomyocyte mitosis postnatally, and homeotic skeletal transformations consistent with Hox cofactor function [PMID:22969701, PMID:26524254, PMID:26218146].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"The initial discovery that BTG1 overexpression inhibits NIH3T3 proliferation and that its expression peaks in G0/G1 established BTG1 as an antiproliferative gene linked to cell cycle exit.\",\n      \"evidence\": \"Transfection of NIH3T3 cells with BTG1 expression vector; Northern blot cell-cycle analysis\",\n      \"pmids\": [\"1373383\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of growth inhibition unknown\", \"No binding partners identified\", \"No in vivo validation\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of PRMT1 as a direct BTG1-interacting partner that modulates arginine methyltransferase activity revealed the first biochemical effector mechanism for BTG1's cellular functions.\",\n      \"evidence\": \"Yeast two-hybrid screen; GST pulldown; in vitro methyltransferase activity assay\",\n      \"pmids\": [\"8663146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrates of PRMT1 methylation downstream of BTG1 unknown\", \"In vivo relevance not yet tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that BTG1 binds CAF1/CCR4-NOT complex components via Box B, with the interaction regulated by CDK2-mediated Ser-159 phosphorylation, established a second major effector axis and linked BTG1 to transcriptional/post-transcriptional regulation via the CCR4 complex.\",\n      \"evidence\": \"Yeast two-hybrid; GST pulldown; Co-IP; in vitro kinase assay with purified CDKs; phosphorylation-site mutagenesis\",\n      \"pmids\": [\"9712883\", \"9820826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CAF1 interaction mediates deadenylation not yet tested\", \"Functional consequence of Ser-159 phosphorylation on cell proliferation unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that BTG1 enhances Hoxb9-mediated transcription by stabilizing Hoxb9 DNA binding expanded the gene's role to transcriptional coactivation beyond the PRMT1 axis, and predicted developmental phenotypes.\",\n      \"evidence\": \"Yeast two-hybrid; GST pulldown; transient transfection reporter assays; EMSA\",\n      \"pmids\": [\"10617598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo Hox-dependent developmental role not demonstrated\", \"Whether BTG1 coactivation is direct or through adaptor recruitment unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of LXXLL nuclear receptor box motifs as required for ERα regulation and mapping of localization signals showed that BTG1 acts as a nuclear transcriptional coactivator of nuclear receptors and that its nuclear localization is essential for myogenic differentiation activity.\",\n      \"evidence\": \"Co-IP; mutagenesis of LXXLL motifs; luciferase reporter assays; β-galactosidase fusion localization assays; myoblast differentiation readouts\",\n      \"pmids\": [\"11136725\", \"11420681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER regulation operates through PRMT1 or CAF1 arm unclear\", \"Endogenous target genes of BTG1-nuclear receptor complexes not identified\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Positioning BTG1 as a FoxO3a transcriptional target that requires its PRMT1-binding domain to block erythroid colony outgrowth placed the BTG1/PRMT1 axis within a defined upstream signaling hierarchy controlling hematopoietic progenitor proliferation.\",\n      \"evidence\": \"Promoter-reporter assays; retroviral overexpression in primary bone marrow cells; colony assays; pharmacological methyltransferase inhibition; domain deletion mutants\",\n      \"pmids\": [\"14734530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PRMT1 substrates mediating erythroid arrest not identified\", \"Whether FoxO3a-BTG1-PRMT1 axis operates in other lineages untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Direct binding of BTG1 to T3R, RAR, and avian MyoD via A box/C-terminal domains, with mutagenesis showing these interactions are required for both transcriptional activation and myogenic differentiation, consolidated BTG1's identity as a multi-nuclear-receptor coactivator.\",\n      \"evidence\": \"Co-IP in myoblasts; GST pulldown with in vitro-translated proteins; transcriptional reporter assays; domain deletion mutagenesis\",\n      \"pmids\": [\"15674337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether coactivation involves PRMT1-dependent chromatin modification at target genes unknown\", \"Genome-wide targets in myogenesis not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration that Box C-mediated PRMT1 binding is required for anti-IgM-induced G1 arrest in B lymphoma cells, confirmed by both siRNA and pharmacological inhibition, established PRMT1 as the essential effector of BTG1 growth arrest in B cells.\",\n      \"evidence\": \"Retroviral overexpression; flow cytometry; PRMT1 siRNA; AdOx inhibition; Box C mutagenesis; immunoprecipitation with anti-dimethylarginine antibody\",\n      \"pmids\": [\"17466295\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the 36-kDa methylated substrate unknown\", \"Whether the CAF1-binding arm also contributes to B cell growth arrest untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"BTG1 was shown to determine glucocorticoid sensitivity in ALL by recruiting PRMT1 to the GR promoter in a BTG1-dependent manner, enabling GR autoinduction — the first ChIP-based evidence placing the BTG1/PRMT1 complex at a defined chromatin locus.\",\n      \"evidence\": \"shRNA knockdown; GR expression rescue; ChIP of PRMT1 at GR promoter; luciferase reporter assays\",\n      \"pmids\": [\"20354172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRMT1-catalyzed histone methylation or non-histone substrate methylation mediates GR induction unclear\", \"Clinical validation in ALL patients lacking\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Btg1 knockout mice revealed that Btg1 is essential for maintaining adult neural stem cell quiescence: loss causes transient hyperproliferation followed by p53/p21-dependent apoptosis and progressive stem cell depletion, providing the first in vivo demonstration that Btg1 safeguards stem cell pools.\",\n      \"evidence\": \"Btg1 KO mice; BrdU/EdU incorporation; immunofluorescence for p53, p21, activated caspase-3; neurosphere self-renewal assay\",\n      \"pmids\": [\"22969701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular targets of BTG1 in neural stem cells not identified\", \"Whether PRMT1 or CAF1 arm mediates quiescence in this niche unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Multiple in vivo studies converged to show BTG1 controls cyclin D1-dependent cerebellar granule precursor proliferation, synergizes with BTG2 in Hox-dependent axial skeleton patterning, and modulates ATF4 methylation at Arg-239 to regulate stress adaptation — establishing BTG1 as a pleiotropic developmental and stress-response regulator acting through distinct molecular effectors.\",\n      \"evidence\": \"Btg1 and Btg1/Btg2 DKO mice; skeletal preparations; cyclin D1 readouts in GCP cell line; co-IP of BTG1-ATF4; in vitro methylation identifying Arg-239; stress survival assays in KO MEFs and B-cell progenitors\",\n      \"pmids\": [\"26524254\", \"26524254\", \"26657730\", \"26396236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cyclin D1 regulation is direct or indirect unclear\", \"Structural basis for ATF4 methylation site selectivity unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"BTG1 was placed within the mTOR/S6K1/CREB regulatory axis in hepatocytes, where it suppresses ATF4-driven SCD1 expression to prevent steatosis and improves insulin sensitivity via c-Jun upregulation, extending its antiproliferative cofactor role to metabolic homeostasis.\",\n      \"evidence\": \"Adenovirus-mediated overexpression/knockdown in vivo; BTG1 transgenic mice; ATF4 overexpression rescue; SCD1 knockdown epistasis; insulin and glucose tolerance tests\",\n      \"pmids\": [\"27188441\", \"26396236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the hepatic metabolic role requires PRMT1 enzymatic activity not directly tested\", \"Human liver disease relevance not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The deadenylation function of BTG1/2 was definitively established: double-knockout T cells showed globally lengthened poly(A) tails and increased mRNA half-lives causing spontaneous activation, while lymphoma-associated BTG1 mutations were shown to disrupt CNOT7/CNOT8 binding and abolish antiproliferative and mRNA decay activity.\",\n      \"evidence\": \"BTG1/2 DKO T cells; RNA-seq; poly(A) tail sequencing; mRNA half-life measurement; functional assays of 16 DLBCL BTG1 variants for CNOT7/CNOT8 binding and antiproliferative activity\",\n      \"pmids\": [\"32165587\", \"33021411\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether specific mRNA targets mediate the quiescence phenotype or the effect is global remains unclear\", \"Relative contribution of PRMT1 versus CAF1/PABPC1 arms to BTG1 tumor suppression in lymphoma unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"NMR-based structural dissection showed the Box C motif is necessary and sufficient for PABPC1 interaction and stimulation of mRNA deadenylation, completing the molecular anatomy of the BTG1 deadenylation axis (Box A/B for CAF1, Box C for PABPC1).\",\n      \"evidence\": \"NMR spectroscopy; Box C mutational analysis; GST pulldown; co-IP; in vitro and cellular deadenylation assays\",\n      \"pmids\": [\"34060423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full structure of BTG1-PABPC1-CAF1 ternary complex not determined\", \"Whether PABPC1 binding is regulated by post-translational modification unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"BTG1 mutations in germinal center B cells were shown to create supercompetitors via altered MYC induction kinetics, and BTG1 loss was found to activate a BCAR1-RAC1 migration pathway targetable by dasatinib, revealing two distinct pathogenic mechanisms in DLBCL.\",\n      \"evidence\": \"Mouse models of BTG1 mutation; competitive GC B cell assays; MYC induction kinetics; Co-IP of BTG1-BCAR1; RAC1 activation and migration assays; dasatinib treatment in vivo\",\n      \"pmids\": [\"36656933\", \"36375119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MYC kinetics shift is mediated through the deadenylation or PRMT1 arm not determined\", \"Clinical efficacy of dasatinib in BTG1-mutant DLBCL unvalidated\", \"BCAR1 interaction domain on BTG1 not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified quantitative model of how the PRMT1-dependent and CAF1/PABPC1-dependent arms of BTG1 are coordinately deployed in different cellular contexts — and which arm is dominant for tumor suppression in specific cancer types — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of full-length BTG1 in complex with both PRMT1 and CAF1/PABPC1\", \"Genome-wide identification of mRNA targets whose deadenylation is BTG1-dependent in normal versus malignant B cells lacking\", \"Context-dependent relative contributions of PRMT1 and deadenylation arms to tumor suppression not dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4, 5, 9, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 7, 10, 15, 18, 19]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 5, 9, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 6, 11]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 10, 13, 24]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 9, 11]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [18, 19, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 13, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 21, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [12, 14, 29]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 17]}\n    ],\n    \"complexes\": [\n      \"CCR4-NOT deadenylase complex\"\n    ],\n    \"partners\": [\n      \"PRMT1\",\n      \"CNOT7\",\n      \"CNOT8\",\n      \"PABPC1\",\n      \"BCAR1\",\n      \"ATF4\",\n      \"HOXB9\",\n      \"NR3C1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}